US 6,479,477 B1Grant

Substituted porphyrins

Issue Date:2002-11-12

•23 Claims

•3 Drawing Sheets

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. Compounds of the invention include those of Formula I.

Metadata

Assignees

Duke University
Aeolus Pharmaceuticals, Inc.

Inventors

James D. Crapo
Brian J. Day
Polivina Jolicia F. Gauuan
Anthony D. Pechulis, Jr.
Michael P. Trova

Application Information

Application Number:US 09/296,615

Filing Date:1999-04-23

Priority Date:1998-04-24

Art Unit:7

Classifications

IPC:

A61K 5104C07D48722

Field of Search:

540145514183514410

Patent Drawings (3 sheets)

Description

[0002] The present application claims benefit of U.S. Provisional Application No. 60/082,881, filed Apr. 24, 1998.

TECHNICAL FIELD

[0003] The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

BACKGROUND

[0004] Oxidants are produced as part of the normal metabolism of all cells but also are an important component of the pathogenesis of many disease processes. Reactive oxygen species, for example, are critical elements of the pathogenesis of diseases of the lung, the central nervous system and skeletal muscle. Oxygen free radicals also play a role in modulating the effects of nitric oxide (NO.). In this context, they contribute to the pathogenesis of vascular disorders, inflammatory diseases and the aging process.

[0005] A critical balance of defensive enzymes against oxidants is required to maintain normal cell and organ function. Superoxide dismutases (SODs) are a family of metalloenzymes that catalyze the intra- and extracellular conversion of O₂⁻ into H₂O₂plus O₂, and represent the first line of defense against the detrimental effects of superoxide radicals. Mammals produce three distinct SODs. One is a dimeric copper- and zinc-containing enzyme (CuZn SOD) found in the cytosol of all cells. A second is a tetrameric manganese-containing SOD (Mn SOD) found within mitochondria, and the third is a tetrameric, glycosylated, copper- and zinc-containing enzyme (EC-SOD) found in the extracellular fluids and bound to the extracellular matrix. Several other important antioxidant enzymes are known to exist within cells, including catalase and glutathione peroxidase. While extracellular fluids and the extracellular matrix contain only small amounts of these enzymes, other extracellular antioxidants are also known to be present, including radical scavengers and inhibitors of lipid peroxidation, such as ascorbic acid, uric acid, and α-tocopherol (Halliwell et al, Arch. Biochem. Biophys. 280:1 (1990)).

[0006] The present invention relates generally to low molecular weight porphyrin compounds suitable for use in modulating intra- and extracellular processes in which superoxide radicals, or other oxidants such as hydrogen peroxide or peroxynitrite, are a participant. The compounds and methods of the invention find application in various physiologic and pathologic processes in which oxidative stress plays a role.

SUMMARY OF THE INVENTION

[0007] The present invention relates to a method of modulating intra- or extracellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals. More particularly, the invention relates to a method of modulating normal or pathological processes involving superoxide radicals, hydrogen peroxide, nitric oxide or peroxynitrite using low molecular weight antioxidants, and to methine (ie, meso) substituted porphyrins suitable for use in such a method.

[0008] Objects and advantages of the present invention will be clear from the description that follows.

BRIEF DESCRIPTION OF THE DRAWING

[0009] FIGS. 1A-1C show the structures of certain compounds of the invention. The SOD activity values were determined using the method of McCord and Fridovich, J. Biol. Chem. 244:6049 (1969). The TBARS values were obtained as follows:

[0010] Homogenates

[0011] Frozen adult Sprague-Dawley rat brains, livers and mouse lungs (Pel-Freez, Rogers, AR) were homogenized with a polytron (Turrax T25, Germany) in 5 volumes of ice cold 50 mM potassium phosphate at pH 7.4. Homogenate protein concentration was determined with the Coomassie Plus protein assay (Pierce, Rockford, Ill.) using bovine serum albumin as a standard. The homogenate volume was adjusted with buffer to give a final protein concentration of 10 mg/ml and frozen as aliquots at −80° C.

[0012] Oxidation of homogenates

[0013] Microfuge tubes (1.5 ml) containing 0.2 ml of homogenate (0.2 mg protein) and various concentrations of antioxidant were incubated at 37° C. for 15 minutes. Oxidation of the rat brain homogenate was initiated by the addition of 0.1 ml of a freshly prepared stock anaerobic solution containing ferrous chloride (0.25 mM) and ascorbate (1 mM). Samples were placed in a shaking water bath at 37° C. for 30 minutes (final volume 1 ml). The reactions were stopped by the addition of 0.1 μL of a stock butylated hydroxytoluene (60 mM) solution in ethanol.

[0014] Lipid peroxidation measurement

[0015] The concentration of thiobarbituric acid reactive species (TBARS) in rat brain homogenates was used as a index of lipid peroxidation. Malondialdehyde standards were obtained by adding 8.2 μL of 1,1,3,3-tetramethoxypropane in 10 ml of 0.01 N HCl and mixing for 10 minutes at room temperature. This stock was further diluted in water to give standards that ranged from 0.25 to 25 μM. Samples or standards (200 μL) were acidified with 200 μL of 0.2 M stock of phosphoric acid in 1.5 ml locking microfuge tubes. The color reaction was initiated by the addition of 25 μL of a stock thiobarbituric acid solution (0.11 M) that was mixed and then placed in a 90° C. heating block for 30 minutes. TBARS were extracted with 0.5 ml of n-butanol by vortexing for 3 minutes and chilling on ice for 1 minute. The samples were then centrifuged at 12,000×g for 3 minutes and a 150 μL aliquot of the n-butanol phase was placed in each well of a 96-well plate and read at 535 nm in a Thermomax platereader (Molecular Devices, Sunnydale, Calif.) at 25° C. Sample absorbances were converted to MDA equivalences (μM) by extrapolation from the MDA standard curve. None of the antioxidants at concentrations employed in these studies affected the reaction of MDA standards with thiobarbituric acid.

[0016] Statistical analyses

[0017] Data were presented as their means±SE. The inhibitory concentration of antioxidants that decreased the degree of lipid peroxidation by 50% (IC₅₀) and respective 95% confidence intervals (CI) were determined by fitting a sigmoidal curve with variable slope to the data (Prizm, GraphPad, San Diego, Calif.). (See also Braughler et al, J. Biol. Chem. 262:10438 (1987); Kikugawa et al, Anal. Biochem. 202:249 (1992).)

DETAILED DESCRIPTION OF THE INVENTION

[0018] The present invention relates to methods of protecting against the deleterious effects of oxidants, particularly, superoxide radicals, hydrogen peroxide and peroxynitrite, and to methods of preventing and treating diseases and disorders that involve or result from oxidant stress. The invention also relates methods of modulating biological processes involving oxidants, including superoxide radicals, hydrogen peroxide, nitric oxide and peroxynitrite. The invention further relates to compounds and compositions, including low molecular weight antioxidants (eg mimetics of scavengers of reactive oxygen species, including mimetics of SODs, catalases and peroxidases) and formulations thereof, suitable for use in such methods.

[0019] Mimetics of scavengers of reactive oxygen species appropriate for use in the present methods include methine (ie meso) substituted porphines, or pharmaceutically acceptable salts thereof (eg chloride or bromide salts). The invention includes both metal-free and metal-bound porphines. In the case of metal-bound porphines, manganic derivatives of methine (meso) substituted porphines are preferred, however, metals other than manganese such as iron (II or III), copper (I or II), cobalt (II or III), or nickel (I or II), can also be used. It will be appreciated that the metal selected can have various valence states, for example, manganese II, III or V can be used. Zn (II) can also be used even though it does not undergo a valence change and therefore will not directly scavenge superoxide. The choice of the metal can affect selectivity of the oxygen species that is scavenged. Iron-bound porphines, for example, can be used to scavenge NO while manganese-bound porphines scavenge less well.

[0020] The mimetics of the present invention are of the Formula I:

[0021] or pharmaceutically acceptable salt thereof wherein:

[0022] R₁and R₃are, independently:

[0023] —CO₂C_1-4alkyl; or

[0024] —CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

[0025] R₂is:

[0026] —H

[0027] —C_1-4alkyl

[0028] —COOH

[0029] —CO₂C_1-4alkyl,

[0030] —CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

[0031] —CON(CH₃)₂, or

[0032] —CX₃, wherein X is halogen; and

[0033] R₄is:

[0034] —H,

[0035] —C_1-4alkyl

[0036] —COOH,

[0037] —CO₂C_1-4alkyl,

[0038] —CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

[0039] —CON(CH₃)₂, or

[0040] —CX₃, wherein X is halogen.

[0041] Preferably, R₁and R₃are, independently, —CO₂C_1-4alkyl (advantageously, —CO₂C_1-3alkyl) or —CO₂CH₂CX₃(advantageously, where X=F), R₂is —H, —CO₂C_1-3alkyl, —CO₂CH₂CX₃(advantageously, where X=F), —CON(CH₃)₂or CX₃(advantageously, where X=F) and R₄is —H, —COOH, —CO₂C_1-3alkyl, —CON(CH₃)₂or —CX₃(advantageously, where X=F).

[0042] More preferably, R₁and R₃are, independently, —CO₂C_1-3alkyl, R₂is —CO₂C_1-3alkyl, —CON(CH₃)₂or —CX₃(advantageously, where X=F), and R₄is —H, —COOH, —CO₂C_1-3alkyl, —CON(CH₃)₂or —CX₃(advantageously, where X=F).

[0043] Still more preferably, R_{1 or R}₃is —CO₂CH₃, —CO₂CH₂CH₃, or —CON(CH₃)₂, R₂is —CO₂CH₃, —CO₂CH₂CH₃, or CX₃(advantageously, where X=F), and R₄is —H, —COOH, —CO₂CH₃, —CO₂CH₂CH₃or CX₃(advantageously, where X=F).

[0044] Even more preferably, R₁, R₂and R₃are, independently, —CO₂CH₃or —CO₂CH₂CH₃, and R₄is —H, —COOH, —CO₂CH₃or —CO₂CH₂CH₃or —CO₂CH₂CH₃.

[0045] Most preferably, R₁, R₂, R₃and R₄are, independently, —CO₂CH₃or —CO₂CH₂CH₃.

[0046] Specific examples of mimetics of the invention are shown in FIG. 1, together with activity data.

[0047] In addition to the methine (meso) substituents described above, one or more of the pyrrole rings of the porphyrin of Formula I can be substituted at any or all beta carbons, ie: 2, 3, 7, 8, 12, 13, 17 or 18. Such substituents, designated P, can be hydrogen or an electron withdrawing group, for example, each P can, independently, be a NO₂group, a halogen (eg Cl, Br or F), a nitrile group, a vinyl group, or a formyl group. Such substituents alter the redox potential of the porphyrin and thus enhance its ability to scavenge oxygen radicals. For example, there can be 1, 2, 3, 4, 5, 6, 7, or 8 halogen (eg Br) substituents (preferably, 1-4), the remaining P's advantageously being hydrogen. When P is formyl, it is preferred that there not be more than 2 (on non-adjacent carbons), more preferably, 1, the remaining P's preferably being hydrogen. When P is NO₂, it is preferred that there not be more than 4 (on non-adjacent carbons), more preferably, 1 or 2, the remaining P's being hydrogen.

[0048] Where isomers are possible, all such isomers of the herein described mimetics are within the scope of the invention.

[0049] Mimetics preferred for use in the present methods can be selected by assaying for SOD, catalase and/or peroxidase activity. Minetics can also be screened for their ability to inhibit lipid peroxidation.

[0050] SOD activity can be monitored in the presence and absence of EDTA using the method of McCord and Fridovich (J. Biol. Chem. 244:6049 (1969)). The efficacy of a mimetic can also be determined by measuring the effect of the mimetic on the aerobic growth of a SOD null E. colistrain versus a parent strain. Specifically, parental E. coli(AB 1157) and SOD null E. coli.(JI132) can be grown in M9 medium containing 0.2% casamino acids and 0.2% glucose at pH 7.0 and 37° C; growth can be monitored in terms of turbidity followed at 700 nm. This assay can be made more selective for SOD mimetics by omitting the branched chain, aromatic and sulphur-containing amino acids from the medium (glucose minimal medium (M9), plus 5 essential amino acids).

[0051] Efficacy of active mimetics can also be assessed by determining their ability to protect mammalian cells against methylviologen (paraquat)-induced toxicity. Specifically, rat L2 cells grown as described below and seeded into 24 well dishes can be pre-incubated with various concentrations of the SOD mimetic and then incubated with a concentration of methylviologen previously shown to produce an LC₇₅in control L2 cells. Efficacy of the mimetic can be correlated with a decrease in the methylviologen-induced LDH release (St. Clair et al, FEBS Lett. 293:199 (1991)).

[0052] The efficacy of SOD mimetics can be tested in vivo with mouse and/or rat models using both aerosol administration and parenteral injection. For example, male Balb/c mice can be randomized into 4 groups of 8 mice each to form a standard 2×2 contingency statistical model. Animals can be treated with either paraquat (40 mg/kg, ip) or saline and treated with SOD mimetic or vehicle control. Lung injury can be assessed 48 hours after paraquat treatment by analysis of bronchoalveolar lavage fluid (BALF) damage parameters (LDH, protein and % PMN) as previously described (Hampson et al, Tox. Appl. Pharm. 98:206 (1989); Day et al, J. Pharm. Methods 24:1 (1990)). Lungs from 2 mice of each group can be instillation-fixed with 4% paraformaldehyde and processed for histopathology at the light microscopic level.

[0053] Catalase activity can be monitored by measuring absorbance at 240 nm in the presence of hydrogen peroxide (see Beers and Sizer, J. Biol. Chem. 195:133 (1952)) or by measuring oxygen evolution with a Clark oxygen electrode (Del Rio et al, Anal. Biochem. 80:409 (1977)).

[0054] Peroxidase activity can be measured spectrophotometrically as previously described by Putter and Becker: Peroxidases. In: Methods of Enzymatic Analysis, H. U. Bergmeyer (ed.), Verlag Chemie, Weinheim, pp. 286-292 (1983). Aconitase activity can be measured as described by Gardner and Fridovich (J. Biol. Chem. 266:19328 (1991)). The selective, reversible and SOD-sensitive inactivation of aconitase by known O⁻₂generators can be used as a marker of intracellular O⁻₂generation. Thus, suitable mimetics can be selected by assaying for the ability to protect aconitase activity.

[0055] The ability of miimetics to inhibit lipid peroxidation can be assessed as described by Ohkawa et al (Anal. Biochem. 95:351 (1979)) and Yue et al (J. Pharmacol. Exp. Ther. 263:92 (1992)). Iron and ascorbate can be used to initiate lipid peroxidation in tissue homogenates and the formation of thiobarbituric acid reactive species (TBARS) measured.

[0056] Active mimetics can be tested for toxicity in mammalian cell culture by measuring lactate dehydrogenase (LDH) release. Specifically, rat L2 cells (a lung Type II like cell (Kaighn and Douglas, J. Cell Biol. 59:160a (1973)) can be grown in Ham's F-12 medium with 10% fetal calf serum supplement at pH 7.4 and 37/C; cells can be seeded at equal densities in 24 well culture dishes and grown to approximately 90% confluence; SOD mimetics can be added to the cells at log doses (eg micromolar doses in minimal essential medium (MEM)) and incubated for 24 hours. Toxicity can be assessed by morphology and by measuring the release of the cytosolic injury marker, LDH (eg on a thermokinetic plate reader), as described by Vassault (In: Methods of Enzymatic Analysis, Bergmeyer (ed) pp. 118-26 (1983); oxidation of NADH is measured at 340 nm).

[0057] Synthesis of various mimetics suitable for use in the present method can be effected using art-recognized protocols (see, for example Sastry et al, Anal. Chem. 41:857 (1969), Pastemack et al, Biochem. 22:2406 (1983); Richards et al, Inorg. Chem. 35:1940 (1996) and U.S. Appln. No. 08/663,028, particularly the details therein relating to syntheses). Synthesis of a number of mimetics of the invention are set forth in the Examples that follow.

[0058] The mimetics of the present invention are suitable for use in a variety of methods. The compounds of Formula I, particularly the metal bound forms (advantageously, the manganese bound forms), are characterized by the ability to inhibit lipid peroxidation. Accordingly, these compounds are preferred for use in the treatment of diseases or disorders associated with elevated levels of lipid peroxidation. The compounds are further preferred for use in the treatment of diseases or disorders mediated by oxidative stress. Inflammation diseases are an example.

[0059] The compounds of the invention (advantageously, metal bound forms thereof) can also be used in methods designed to regulate NO. levels by targeting the above-described porphines to strategic locations. NO. is an intercellular signal and, as such, NO. must traverse the extracellular matrix to exert its effects. NO., however, is highly sensitive to inactivation mediated by O₂⁻ present in the extracellular spaces. The methine (meso) substituted porphyrins of the invention can increase bioavailability of NO. by preventing its degradation by O₂⁻.

[0060] The present invention relates, in a further specific embodiment, to a method of inhibiting production of superoxide radicals. In this embodiment, the mimetics of the invention (particularly,metal bound forms thereof) are used to inhibit oxidases, such as xanthine oxidase, that are responsible for production of superoxide radicals. The ability of a mimetic to protect mammalian cells from xanthine/xanthine oxidase-induced injury can be assessed, for example, by growing rat L2 cells in 24-well dishes. Cells can be pre-incubated with various concentrations of a mimetic and then xanthine oxidase (XO) can be added to the culture along with xanthine (X). The appropriate amount of XO/X used in the study can be pre-determined for each cell line by performing a dose-response curve for injury. X/XO can be used in an amount that produces approximately an LC₇₅in the culture. Efficacy of the mimetic can be correlated with a decrease in XO/X-induced LDH release.

[0061] The mimetics of the invention (particularly, metal bound forms thereof) can also be used as catalytic scavengers of reactive oxygen species to protect against ischemia reperfusion injuries associated with myocardial infarction, stroke, acute head trauma, organ reperfusion following transplantation, bowel ischemia, hemorrhagic stock, pulmonary infarction, surgical occlusion of blood flow, and soft tissue injury. The mimetics (particularly, metal bound forms) can further be used to protect against skeletal muscle reperfusion injuries. The mimetics (particularly, metal bound forms) can also be used to protect against damage to the eye due to sunlight (and to the skin) as well as glaucoma, and macular degeneration of the eye. Diseases of the bone are also amenable to treatment with the mimetics. Further, connective tissue disorders associated with defects in collagen synthesis or degradation can be expected to be susceptible to treatment with the present mimetics (particularly, metal bound forms), as should the generalized deficits of aging.

[0062] The mimetics of the invention (particularly, metal bound forms) can also be used as catalytic scavengers of reactive oxygen species to increase the very limited storage viability of transplanted hearts, kidneys, skin and other organs and tissues. The invention also provides methods of inhibiting damage due to autoxidation of substances resulting in the formation of O₂⁻ including food products, pharmaceuticals, stored blood, etc. To effect this end, the mimetics of the invention are added to food products, pharmaceuticals, stored blood and the like, in an amount sufficient to inhibit or prevent oxidation damage and thereby to inhibit or prevent the degradation associated with the autoxidation reactions. (For other uses of the mimetics of the invention, see U.S. Pat. No. 5,227,405). The amount of mimetic to be used in a particular treatment or to be associated with a particular substance can be determined by one skilled in the art.

[0063] The mimetics (particularly, metal bound forms) of the invention can further be used to scavenge hydrogen peroxide and thus protect against formation of the highly reactive hydroxyl radical by interfering with Fenton chemistry (Aruoma and Halliwell, Biochem. J. 241:273 (1987); Mello Filho et al, Biochem. J. 218:273 (1984); Rush and Bielski, J. Phys. Chem. 89:5062 (1985)). The mimetics (particularly, metal bound forms) of the invention can also be used to scavenge peroxynitrite, as demonstrated indirectly by inhibition of the oxidation of dihydrorhodamine 123 to rhodamine 123 and directly by accelerating peroxynitrite degradation by stop flow analysis.

[0064] Further examples of specific diseases/disorders appropriate for treatment using the mimetics of the present invention, advantageously, metal bound forms, include diseases of the central nervous system (including AIDS dementia, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease and Huntington's disease) and diseases of the musculature (including diaphramic diseases (eg respiratory fatigue in emphysema, bronchitis and cystic fibrosis), cardiac fatigue of congestive heart failure, muscle weakness syndromes associated with myopathies, ALS and multiple sclerosis). Many neurologic disorders (including stroke, Huntington's disease, Parkinson's disease, ALS, Alzheimer's and AIDS dementia) are associated with an over stimulation of the major subtype of glutamate receptor, the NMDA (or N-methyl-D-aspartate) subtype. On stimulation of the NMDA receptor, excessive neuronal calcium concentrations contribute to a series of membrane and cytoplasmic events leading to production of oxygen free radicals and nitric oxide (NO.). Interactions between oxygen free radicals and NO. have been shown to contribute to neuronal cell death. Well-established neuronal cortical culture models of NMDA-toxicity have been developed and used as the basis for drug development. In these same systems, the mimetics of the present invention inhibit NMDA induced injury. The formation of O⁻₂radicals is an obligate step in the intracellular events culminating in excitotoxic death of cortical neurons and further demonstrate that the mimetics of the invention can be used to scavenge O⁻₂radicals and thereby serve as protectants against excitotoxic injury.

[0065] The present invention also relates to methods of treating AIDS. The Nf Kappa B promoter is used by the HIV virus for replication. This promoter is used by the HIV virus for replication. This promoter is redox sensitive, therefore, an oxidant can regulate this process. This has been shown previously for two metalloporphyrins distinct from those of the present invention (Song et al, Antiviral Chem. and Chemother. 8:85 (1997)). The invention also relates to methods of treating arritis, systemic hypertension, atherosclerosis, edema, septic shock, pulmonary hypertension, including primary pulmonary hypertension, impotence, infertility, endometriosis, premature uterine contractions, microbial infections, gout and in the treatment of Type II diabetes mellitus. The mimetics of the invention (particularly, metal bound forms) can be used to ameliorate the toxic effects associated with endotoxin, for example, by preserving vascular tone and preventing multi-organ system damage.

[0066] As indicated above, inflammations, particularly inflammations of the lung, are amenable to treatment using the present mimetics (articularly, metal bound forms) (note particularly the inflammatory based disorders of asthma, ARDS including oxygen toxicity, pneumonia (especially AIDS-related pneumonia), cystic fibrosis, chronic sinusitis and autoimmune diseases (such as rheumatoid arthitis)). EC-SOD is localized in the interstitial spaces surrounding airways and vasculature smooth muscle cells. EC-SOD and O₂⁻ mediate the antiinflammatory-proinflammatory balance in the alveolar septum. NO. released by alveolar septal cells acts to suppress inflammation unless it reacts with O₂⁻ to form ONOO⁻. By scavenging O₂⁻, EC-SOD tips the balance in the alveolar septum against inflammation. Significant amounts of ONOO⁻ will form only when EC-SOD is deficient or when there is greatly increased O₂⁻ release. Mimetics described herein can be used to protect against destruction caused by hyperoxia.

[0067] The invention further relates to methods of treating memory disorders. It is believed that nitric oxide is a neurotransmitter involved in long-term memory potentiation. Using an EC-SOD knocked-out mouse model (Carlsson et al, Proc. Natl. Acad. Sci. USA 92:6264 (1995)), it can be shown that learning impairment correlates with reduced superoxide scavenging in extracellular spaces of the brain. Reduced scavenging results in higher extracellular O⁻₂ levels. O⁻₂is believed to react with nitric oxide thereby preventing or inhibiting nitric oxide-mediated neurotransmission and thus long-term memory potentiation. The mimetics of the invention, particularly, metal bound forms, can be used to treat dementias and memory/learning disorders.

[0068] The availability of the mimetics of the invention also makes possible studies of processes mediated by O₂⁻, hydrogen peroxide, nitric oxide and peroxynitrite.

[0069] The miimetics described above, metal bound and metal free forms, can be formulated into pharmaceutical compositions suitable for use in the present methods. Such compositions include the active agent (mimetic) together with a pharmaceutically acceptable carrier, excipient or diluent. The composition can be present in dosage unit form for example, tablets, capsules or suppositories. The composition can also be in the form of a sterile solution suitable for injection or nebulization. Compositions can also be in a form suitable for opthalmic use. The invention also includes compositions formulated for topical administration, such compositions taking the form, for example, of a lotion, cream, gel or ointment. The concentration of active agent to be included in the composition can be selected based on the nature of the agent, the dosage regimen and the result sought.

[0070] The dosage of the composition of the invention to be administered can be determined without undue experimentation and will be dependent upon various factors including the nature of the active agent (including whether metal bound or metal free), the route of administration, the patient, and the result sought to be achieved. A suitable dosage of mimetic to be administered IV or topically can be expected to be in the range of about 0.01 to 50 mg/kg/day, preferably, 0.1 to 10 mg/kg/day. For aerosol administration, it is expected that doses will be in the range of 0.001 to 5.0 mg/kg/day, preferably, 0.01 to 1 mg/kg/day. Suitable doses of mimetics will vary, for example, with the mimetic and with the result sought.

[0071] Certain aspects of the present invention will be described in greater detail in the non-limiting Examples that follow.

EXAMPLE 1

I. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (3), [5-Carboxy-10,15,20-tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (4) and [5,10,15Tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (5)

[0072]

[0073] 1. 5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrin (2)

[0074] In a foil covered, 22 L three-neck round-bottom flask equipped with a mechanical stirrer and a N₂inlet was added consecutively, freshly distilled ethyl glyoxylate (Hook, J. M. Synth. Commun.1984, 14, 83-87) (19.3 g, 189 mmol), CH₂Cl₂(19 L), NaCl (1.1 g, 19 mmol) and pyrrole (13.1 mL, 189 mmol). The reaction mixture was stirred for 5-10 min then BF₃.OEt₂(7.0 mL, 56 mmol) was added dropwise. After a ring period of 1.25 h at room temperature, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 32.2 g, 142 mmol) was added. The reaction mixture was stirred for an additional 2 h at room temperature, then clay (Clarion 550, 99 g) was added and the reaction mixture was stirred overnight. Filtration of the heterogeneous mixture through Celite, followed by evaporation of solvents provided a solid mixture which was then adsorbed onto silica gel (24 g). Repeated chromatographic purifications (5 batches; CH₂Cl₂as eluent) on silica gel provided compound 4 (1.7 g; 6%) as a dark solid: ¹H NMR (300 MHz, CDCl₃) δ −3.33 (s, 2H), 1.81 (t, 12H), 5.11 (q, 8H), 9.52 (s, 8H); ¹³C NMR (75 MHz, CDCl₃) δ14.97, 63.67, 112.43, 131.64, 145.30, 170.68.

[0075] 2. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (3)

[0076] A solution of 2 (4.43 g, 7.4 mmol) and MnCl₂(4.67 g, 37.1 mmol) in DMF (500 mL) was heated at 145° C. for 1-1.5 h then exposed to a stream of air. The reaction mixture was heated for an additional 2-3 h then allowed to cool to room temperature overnight and under a stream of air. Evaporation of the DME provided a solid mixture which was adsorbed onto silica gel (24 g). Purification by column chromatography (6 batches; gradient elution 0→7% MeOH/CH₂Cl₂) provided porphyrin 3 (4.3 g; 84%/) as a dark solid: mp>300° C.; UV-vis λ_max=456 nm, ε=1.08×10⁵L/cm-mole; FAB MS m/z=651 [C₃₂H₂₈MnN₄O₈]⁺.

[0077] 3. [5-Carboxy-10,15,20-tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (4) and [5,10,15-Tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (5)

[0078] Porphyrins 4 and 5 were also isolated during the chromatographic purification of the previous reaction. Porphyrin 4: mp>300° C.; UV-vis spectroscopy λ_max=460.5 nm, ε=7.8×10⁴L/cm-mole; FAB MS m/z=623 [C₃₀H₂₄MnN₄O₈]⁺. Porphyrin 5: mp>300° C.; UV-vis spectroscopy λ_max=454.5 nm, ε=1.14×10⁵L/cm-mole; FAB MS m/z=579 [C₂₉H₂₄MnN₄O₆]⁺.

EXAMPLE 2

II. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]zinc(II) (6)

[0079]

[0080] 1. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]zinc(II) (6)

[0081] A solution of 2 (110 mg, 0.18 mmol) and Zn(OAc)₂(403 mg, 18 mmol) in DMF (25 mL) was heated at 145-150° C. for 2 h. The reaction mixture was allowed to cool to room temperature then the DMF was removed by concentration in vacuo. The resulting crude solid mixture was adsorbed onto silica gel (3 g) then purified by column chromatography (gradient elution 0→1% MeOH/(CH₂Cl₂) to provide 6 as a violet solid in 82% yield: mp>300° C., UV-vis spectroscopy λ_max=412.5 nm, ε=2.8×10⁵L/cm-mole; FAB MS m/z=660 [C₃₂H₂₈N₄O₈Zn]⁺; ¹H NMR (300 MHz, DMSO-d₆) δ1.79 (t, 12H), 5.09 (q, 8H), 9.56 (s, 8H); ¹³C NMR (75 MHz, DMSO-d₆) δ14.50, 63.16, 112.57, 132.03, 147.55, 170.67.

EXAMPLE 3

III. [5,10,15,20-Tetrakis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (9) and [5-Carboxy-10,15,20-tris(methoxycarbonyl)porphyrinato]manganese(III) Chloride (10)

[0082]

[0083] 1. 5,10,15,20-Tetrakis(methoxycarbonyl)porphyrin (8)

[0084] In a foil covered, 22 L three-neck round-bottomed flask equipped with a mechanical stirrer and a N₂inlet was added sequentially, freshly distilled methyl glyoxylate (7) (Hook, J. M. Synth. Commun.1984, 14, 83-87) (16.5 g, 187 mmol), CH₂Cl₂(19 L), and pyrrole (13.0 mL, 194 mmol). The reaction mixture was stirred for 5-10 min then BF₃.OEt₂(2.30 mL, 18.7 mmol) was added dropwise. After a stirring period of 1.25 h at room temperature, DDQ (31.9 g, 140.4 mmol) was added. The reaction mixture was stirred for an additional 2.25 h at room temperature, then clay (Clarion 550, 25 g) was added and the suspension was stirred for 2.5 h. Filtration of the reaction mixture through Celite provided, after evaporation of solvents, a crude solid mixture which was adsorbed onto silica gel (15 g). Repeated chromatographic purification (5 batches; CH₂Cl₂as eluent) on silica gel provided porphyrin 8 (1.55 g, 6.1%) as a solid: ¹H NMR (300 MHz, CDCl₃) δ −3.42 (s, 2H), 4.60 (s, 12H), 9.48 (s, 4H); UV-vis λ_max=404.5 nm.

[0085] 2. [5,10,15,20-Tetrakis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (9)

[0086] A solution of 8 (1.11 g, 2.0 mmol) and MnCl₂(1.3 g, 10.3 mmol) in DMF (100 mL) was heated at 145° C. for 1-1.5 h then exposed to a stream of air. The reaction mixture was heated for an additional 2-3 h. The reaction mixture was allowed to cool to room temperature overnight under a stream of air. Evaporation of the DMF provided a solid mixture which was adsorbed onto silica gel (3.5 g). Purification by column chromatography (2 batches; gradient elution 0→10% MeOH/CH₂Cl₂) provided porphyrin 9 (760 mg; 59%): mp>300° C.; UV-vis λ_max=455.5 nm, ε=8.8×10⁴L/cm-mole; FAB MS m/z=595 [C₂₈H₂₀MnN₄O₈]⁺.

[0087] 3. [5-Carboxy-10,15,20-tris(methoxycarbonyl)porphyrinato]manganese(III) Chloride (10)

[0088] Porphyrin 10 was also isolated by chromatography from the metalation process above: mp>300° C.; UV-vis λ_max=459.5 nm, ε=8.5×10⁴L/cm-mole; FAB MS m/z=581 [C₂₇H₁₈MnN₄O₈]⁺.

EXAMPLE 4

IV. [5,15-Bis(methoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrinato]manganese(III) Chloride (15) and [5,15-Bis(trifluoromethyl)-10-carboxy-20-(methoxycarbonyl)porphyriato]manganese(III) Chloride (16)

[0089]

[0090] 1. meso-(Trifluoromethyl)dipyrromethane (12) (Nishino, N.; Wagner, R. W.; Lindsey, J. S. J. Org. Chem.1996, 61, 7534-7544.)

[0091] In a 250 mL round-bottomed flask, equipped with a magnetic stirrer and N₂inlet was placed trifluoracetaldehyde hydrate (11, 6.7 g, 58 mmol), pyrrole (8.0 mL, 116 mmol), and CH₂Cl₂(200 mL). Trifluorocetic acid (4.5 mL, 58 mmol) was then added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was transferred to a separatory funnel, then washed consecutively with H₂O (75 mL) and saturated aqueous NaHCO₃(60 mL). The organic layer was dried (Na₂SO₄), filtered, and the solvent removed in vacuo. Column chromatography of the residue provided 12 (2.07 g; 17%) and 13. Dipyrromethane 12: ¹H NMR (300 MHz, CDCl₃) δ4.85 (q, 1H), 6.19 (m, 4H), 6.77 (m, 2H), 8.09 (broad s, 2H). Tripyrrane 13: ¹H NMR (300 MHz, CDCl₃) δ4.73 (m, 2H), 6.34 (m, 6H), 6.75 (m, 2H), 7.95 (broad s, 1H), 8.09 (broad s, 2H); DI MS m/z=361 [C₁₆H₁₂N₃F₆+H]³⁰.

[0092] 2. 5,15-Bis(methoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrin (14)

[0093] In a foil covered, 500 ml three-neck round-bottomed flask equipped with a magnetic stirrer and a N₂inlet was added consecutively, freshly distilled methyl glyoxylate (Hook, J. M. Synth. Commun.1984, 14, 83-87) (244 mg, 2.77 mmol), dipyrromethane 12 (590 mg, 2.75 mmol) and CH₂Cl₂(280 mL). The reaction mixture was stirred for 5-10 min then BF₃.OEt₂(112 μL, 0.92 mmol) was added. After stirring period of 2 h at room temperature, DDQ (945 mg 4.1 mmol) was added. The reaction mixture was stirred for an additional 2 h at room temperature, then the solvent was removed in vacuo. The residue was adsorbed onto silica gel (3.8 g) then purified by column chromatography (CH₂Cl₂as eluent) to provide porphyrin 14 (390 mg; 30%): ¹H NMR (300 MHz, CDCl₃) δ −2.96 (s, 2H), 4.60 (s, 6H), 9.44 (d, 4H), 9.73 (m, 4H).

[0094] 3. [5,15-Bis(methoxycarbony)-10,20-bis(trafluoromethyl)porphyrinato]manganese(III) Chloride (15)

[0095] A solution of 14 (115 mg, 0.20 mmol) and MnCl₂(130 mg, 1.0 mmol) in DMF (30 mL) was heated at 145° C. overnight. The reaction mixture was cooled to room temperature while exposed to a stream of air. Evaporation of DMF provided a solid mixture which was adsorbed onto 3 g silica gel. Purification by column chromatography (gadient elution with 3-10%MeOH/CH₂Cl₂) provided porphyrin 15 (117 mg): mp>300° C.; UV-vis λ_max=450 nm, ε=9.90×10⁴L/cm-mol; FAB MS m/z=615 [C₂₆H₁₄F₆MnN₄O₄]⁺.

EXAMPLE 5

V. [5,15-Bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (21)

[0096]

[0097] 1. 5,15-Bis(ethoxycarbonyl)porphyrin (18)

[0098] In a foil covered 250 mL round-bottom flask equipped with a magnetic stir bar and a N₂inlet was added consecutively ethyl glyoxylate (50% in toluene; 310 mg, 1.5 mmol), CH₂Cl₂(150 mL) and dipyrromethane 17 (222 mg, 1.5 mmol) (Chong, et al., Aust. J. Chem.1969, 22, 229.) The reaction mixture was stirred for 5-10 min, then BF₃.OEt₂(37 μL, 0.3 mmol) was added. After a 30 min stirring period, DDQ (258 mg, 1.14 mmol) was added and the solution was stirred overnight. The crude material was adsorbed onto silica gel (3 g) and was purified by column chromatography (gradient elution with 50→75% CH₂Cl₂/hexane) to provide porphyrin 18 (22 mg; 7%): ¹H NMR (300 MHz, CDCl3) δ −3.2 (s, 2H), 1.9 (m, 6H), 5.15 (m, 4H), 9.5 (m, 4H), 9.7 (m, 4H) 10.4 (s,2H).

[0099] 2. 5-(Ethoxycarbonyl)porphyrin (19) and Porphyrin (20)

[0100] Porphyrins 19 (10 mg; 2%) and 20 (3 mg; 0.5%), were isolated during chromatographic purification of the previous reaction mixture. For porphyrin 19: ¹H NMR (300 MHz, CDCl₃) δ −3.74 (s, 2H), 1.87 (t, J=6.9 Hz), 5.16-5.13 (m, 2H), 9.43 (s, 4H), 9.49-9.47 (m, 2H), 9.65 (m, 2H), 10.26 (s, 1H), 10.31 (s, 2H); FAB MS m/z=382 [C₂₃H₁₈N₄O₂]⁺.

[0101] 3. [5,15-Bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (21)

[0102] A solution of porphyrin 18 (22 mg, 0.058 mmol), MnCl₂(55 mg, 0.44 mmol) and anhydrous DMF (8 mL) was heated at 125° C. in a round-bottom flask fitted with a reflux condenser. After 1 h, the reaction mixture was exposed to a stream of air and the solution was stirred overnight. The reaction mixture was allowed to cool to room temperature, then the solvent was evaporated in vacuo. The crude solid material was absorbed onto silica gel (1.2 g) and purified by column chromatography (gradient elution 0→7% MeOH/CH₂Cl₂) to provide 21 (6 mg; 19%) as a dark solid: mp>300° C.; UV-vis λ_max=452.5nm, ε=2.48×10⁴L/cm-mol; FAB MS m/z=507 [C₂₆H₂₀MnN₄O₄]⁺.

EXAMPLE 6

VI. [5,10,15,20-Tetrakis(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (27)

[0103]

[0104] 1. Di-n-propyl d-tartrate (24)

[0105] d-Tartaric acid (2.56 g, 17.0 mmol), n-propanol (30 mL) and concentrated H₂SO₄(6 mL) were heated under reflux for 3 d. The solution was cooled to room temperature then partitioned between H₂O and CH₂Cl₂. The organic layer was washed consecutively with aqueous saturated NaHCO₃, H₂O, and brine, then dried (Na₂SO₄), filtered, and the solvent removed in vacuo. The resulting crude ester 24 (2.6 g, 65%) was used without further purification: ¹H NMR (300 MHz, CDCl₃) δ1.0 (t, 6H), 1.75 (m 2H), 3.2 (two singlets, 2H), 4.25 (m, 4H), 4.55 (m 2H); DI MS m/z=235 [C₁₀H₁₈O₆+H]⁺.

[0106] 2. n-Propyl Glyoxylate (25)

[0107] A solution of di-n-propyl d-tartrate (24, 0.73 g, 3.1 mmol) in anhydrous ether (10 mL) was magnetically stirred at 0° C. under dry N₂, as periodic acid dihydrate (0.711 g, 3.12 mmol) was added. The resulting solution was stirred for 1 h. Anhydrous Na₂SO₄was added and the resulting milky solution was filtered, and the solvent was evaporated in vacuo to provide 25 as an oil (0.670 g; 93%): CI MS (methane) m/z=117 [C₅H₈O₃+H]⁺.

[0108] 3. 5,10,15,20-Tetrakis(n-propoxycarbonyl)porphyrin (26)

[0109] To a foil covered, 2 L three-neck round-bottom flask equipped with a magnetic stirrer and a N₂inlet was added consecutively 25 (1.31 g, 11.3 mmol), CH₂Cl₂(1.1 L) and pyrrole (0.78 ml, 11.2 mmol). The reaction mixture was stirred for 5 min, then BF₃.OEt₂(416 μL, 3.3 mmol) was added. After a stirring period of 3.5 h, DDQ (1.92 g, 8.5 mmol) was added to the reaction mixture and stirring continued for an additional 2 h at room temperature. Clay (Clarion 550 clay, 6 g) was added and the reaction mixture was allowed to stir overnight. Filtration of the heterogeneous mixture through Celite followed by removal of the solvent in vacuo provided a solid mixture which was adsorbed onto silica gel (2.5 g). Chromatographic purification (gradient elution 66-100% CH₂Cl₂/hexanes) provided 27 (130 mg; 7%) as a solid: ¹H NMR (300 MHz, CDCl₃) δ −3.31 (s, 2H), 1.29 (t, 12H), 2.18 (m, 8H), 5.02 (7, 8H), 9.52 (s, 8H).

[0110] 4. [5,10,15,2-Tetrakis(n-propoxycarbonyl)porphyrnato]manganese(III) Chloride (27)

[0111] A solution of porphyrin 26 (170 mg, 0.260 mmol) and MnCl₂(167 mg, 1.32 mmol) in DNF was heated at 145° C. for 2 h then exposed to a stream of air. The reaction mixture was heated for another 2-3 h then cooled to room temperature overnight under a stream of air. Evaporation of DMF in vacuo provided a solid mixture which was adsorbed onto silica gel (2.6 g). Purification by column chromatography (elution with 2.5% MeOH/CH₂Cl₂) provided 27 (170 mg; 88%) as a dark solid: mp>300° C.; UV-vis λ_max=456 nm, ε=1.35×10⁵L/cm-mol; FAB MS m/z=707 [C₃₆H₃₆MnN₄O₈]⁺.

EXAMPLE 7

VII. [5,15-Bis(n-propoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrinato]manganese(I) Chloride (29)

[0112]

[0113] 1. 5,15-Bis(n-propoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrin (28)

[0114] In a foil covered, 250 mL three-neck round-bottomed flask equipped with a magnetic stirrer and a N₂inlet was added consecutively n-propyl glyoxylate (25; 154 mg, 1.3 mmol), dipyrromethane 12 (283 mg, 1.3 mmol) and CH₂Cl₂(130 mL). The reaction mixture was stirred for 5-10 min then BF₃.OEt₂(32 μL, 0.26 mmol) was added. After 1.5 h at room temperature, DDQ (225 mg, 1.0 mmol) was added. The reaction mixture was stirred for all additional 2 h at room temperature, then treated with clay (Clarion 550, 500 mg). Filtration of the reaction mixture through Celite, followed by evaporation of solvents provided a residue which was absorbed onto silica gel (2.5 g). Column chromatography (elution with 50% CH₂Cl₂/hexanes) provided porphyrin 28 (15 mg; 3.7%) as a solid: ¹H NMR (300 MHz, CDCl₃) δ −2.94 (s, 2H), 1.3 (m, 6H), 2.2 (m, 4H), 5.04(t, 4H), 9.46 (d, 4H), 9.74(m, 4H).

[0115] 2. [5,15-Bis(n-propoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrinato]manganese(III) Chloride (29)

[0116] A solution of 28 (15 mg, 0.02 mmol) and MnCl₂(28 mg, 0.22 mmol) in DMF (10 mL) was heated at 145° C. while exposed to a stream of air. After analysis by UV-vis indicated that the reaction was complete, the reaction mixture was cooled to room temperature. Evaporation of DMF provided a solid mixture which was absorbed onto silica gel (1.5 g). Purification by column chromatography (gradient elution with 0→2.5% MeOH/CH₂Cl₂) provided porphyrin 28 (15 mg; 87%): UV-vis λ_max=450.5 nm, ε=1.10×10⁵L/cm-mol; FAB MS m/z=671 [C₃₀H₂₂F₆MnN₄O₄]⁺.

EXAMPLE 8

VIII. [5,15-Bis(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (32) and [5-(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (33)

[0117]

[0118] 1. 5-(n-Propoxycarbonyl)porphyrin (30) and 5,15-Bis(n-propoxycarbonyl)porphyrin (31)

[0119] To a foil covered round-bottom flask equipped with a magnetic stirrer and a N₂inlet was added consecutively dipyrromethade 17 (Chong, et al., Aust. J. Chem.1969, 22, 229) (0.63 g, 4.3 mmol), CH₂Cl₂(430 mL), n-propyl glyoxylate (25, 0.5 g, 4.3 mmol) and NaCl (23 mg, 0.43 mmol). The reaction mixture was stirred for 5-10 min, then BF₃.OEt₂(160 μL, 1.3 mmol) was added. After a 65 min stirring period, DDQ (732 mg, 3.23 mmol) was added and the reaction mixture was stirred overnight. Removal of solvents in vacuo provided a crude product which was adsorbed onto silica gel (2 g). Column chromatographic purification (gradient elution with 50%→80% CH₂Cl₂/hexane) afforded porphyrin 20, porphyrin 30 (10 mg, 1.2%) and porphyrin 31 (30 mg, 2.9%): For porphyrin 30: ¹H NMR (300 MHz, CDCl₃) δ −3.62 (s, 2H), 1.31 (t, 3H), 2.24 (m, 2H), 5.04 (t, 2H), 9.48 (d, 2H), 9.51 (m, 4H), 9.70 (d, 2H), 10.33 (s, 1H), 10.36 (s, 2H). For porphyrin 31: ¹H NMR (300 MHz, CDCl₃) δ −3.33 (s, 2H), 1.31 (t, 6H), 2.24 (m, 4H), 5.03 (t, 4H), 9.47 (d, 4H), 9.69 (d, 4H), 10.38 (2H).

[0120] 2. [5,15-Bis(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (32)

[0121] To a magnetically stirred solution of porphyrin 31 (30 mg, 0.062 mmol) in anhydrous DMF (25 mL) was added MnCl₂(39 mg, 0.27 mmol). The reaction flask was fitted with a reflux condenser and the solution was heated to 145° C. for 2 h then exposed to a stream of air. The reaction mixture was heated for an additional 34 h then the solution was allowed to cool to room temperature for 48 h under a stream of air. Evaporation of DMF in vacuo provided a crude product that was adsorbed onto silica gel (2 g). Purification by column chromatography (gradient elution with 5→7.5% MeOH/CH₂Cl₂) provided 30 (35 mg; 98%) as a dark solid: mp>300° C.; UV-vis λ_max=452. nm, ε=6.10×10⁴L/cm-mole; FAB MS m/z=535 [C₂₈H₂₄MnN₄O₄]⁺.

EXAMPLE 9

IX. [5,10,15,20-Tetrakis(2,2,2-trifluoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (37)

[0122]

[0123] 1. Di-(2,2,2-trifluoroethyl) d-tartrate (34)

[0124] d-Tartaric acid (23; 25 g, 0.17 mol), trifluoroethanol (200 ml) and H₂SO₄(59 mL) were magnetically stirred and heated under reflux for 22 h. The solution was cooled to room temperature, partitioned between H₂O and CH₂C₂. The H₂O layer was extracted with CH₂Cl₂(2×150 mL). The combined organic layers were washed with saturated aqueous NaHCO₃, and brine, then filtered through a bed of Celite and evaporated in vacuo. The residue was dissolved in ethyl ether and filtered through a plug of silica. The silica was rinsed with ca. 600 mL. The ether was removed in vacuo and the residue was recrystallized from ether/hexane to yield 34 (17.3; 33%) as white crystals: mp 77-79° C.; ¹H NMR (300 MHz, CDCl₃) δ3.13 (two singlets, 2H), 4.6 (m, 6H).

[0125] 2. 2,2,2-Trifluoroethyl glyoxylate (35)

[0126] A solution of 34 (1 g, 3.2 mmol) in anhydrous ether (25 mL) was magnetically stirred at 0° C. under dry N₂as periodic acid dihydrate (0.72 g, 3.2 mmol) was added in portions (3×0.24 g) over the course of 1 h. The solution was stirred for an additional 4 h. The reaction solution was decanted, dried (NaSO₄), filtered and the solvent removed in vacuo. The material was used immediately and without further purification (0.85 g, 86%).

[0127] 3. 5,10,15,20-Tetrakis(2,2,2-trifluoroethoxycarbonyl)porphyrin (36)

[0128] To a foil covered round-bottomed flask equipped with a magnetic stirrer and N₂inlet was added sequentially 2,2,2-trifluoroethyl glyoxylate 33 (0.85 g, 5.4 mmol), CH₂Cl₂(550 mL) and pyrrole (0.38 mL, 5.4 mmol). The reaction mixture was stirred for 5 min then BF₃.OEt₂(0.20 mL, 1.62 mmol) was added. The reaction mixture was allowed to stir. After a 1.5 h stirring period, DDQ (0.927 g, 4 mmol) was added and the reaction mixture was allowed to stir an additional 30 min. Clay (Clarion 550, 4.17 g) was added and the resulting suspension was stirred for 1 h, then the entire solution was filtered through a bed of Celite. The filtrate was evaporated and adsorbed onto silica gel (2.5 g). Chromatography of the residue on silica (elution with 50-66% CH₂Cl₂/hexanes) provided 36 (37 mg; 3.4%) as a solid: ¹H NMR (300 MHz, CDCl₃) δ −3.6 (s, 2H), 5.5 (q, 8H), 9.5 (s, 8H).

[0129] 4. [5,10,15,20-Tetrakis(2,2,2-trifuoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (37)

[0130] To a round-bottom flask equipped with a magnetic stirrer and a condenser was added porphyrin 36 (36 mg, 0.043 mmol), MnCl₂(27 mg, 0.21 mmol) and DMF (10 ml). The reaction mixture was heated to 140° C. for 2 h, then exposed to a stream of air. After 5 h, an additional amount of MnCl₂(27 mg, 0.21 mmol) was added and the reaction mixture was stirred for 3 d at 100° C. The solvent was removed in vacuo and the residue was adsorbed onto silica gel (1 g). Chromatography on silica gel (gradient elution 0→3% MeOH/CH₂Cl₂) provided porphyrin 37 (23 mg; 58%) as a dark solid: FAB MS m/z=867 [C₃₂H₁₆F₁₂MnN₄O₈]⁺; UV-visλ_max=453.5 nm, ε=7.30×10⁴L/cm-mol.

EXAMPLE 10

X. [5,10,15,20-Tetrakis(n-butoxycarbonyl)porphyinato]manganese(III) Chloride (41) and [5Carboxy-10,15,20-tris(n-butoxycarbony)porphyrinato]manganese(III) Chloride (42)

[0131]

[0132] 1. Di-n-butyl d-tartrate (38)

[0133] d-Tartaric acid (25 g, 167 mmol), n-butanol (200 mL) and concentrated H₂SO₄(59 mL) were heated under reflux overnight. The solution was cooled to room temperature then partitioned between H₂O and CH₂Cl₂. The organic layer was washed with aqueous saturated NaHCO₃then filtered through Celite. The organic solution was then washed with brine, dried (MgSO₄), filtered, and the solvent removed in vacuo. The resulting oil was purified by Kugelrohr distillation (bp=100-105° C., 0.06 mm Hg) to yield 38 as a clear light yellow oil: ¹H NMR (300 MHz, CDCl₃) δ0.9 (t, 6H), 1.4 (m, 4H), 1.65 (m, 4H), 3.2 (m, 2H), 4.35 (m, 4H), 4.5 (m, 2H).

[0134] 2. n-Butyl Glyoxylate (39)

[0135] A solution of tartrate 38 (5 g, 19 mmol) in anhydrous ether (150 mL) was magnetically stirred at 0° C. and under dry N₂, as periodic acid dehydrate (4.35 g, 19 mmol) was added over 1 h in portions (3×1.45 g). The resulting solution was stirred for 4 h, decanted from the solid precipitate, dried (Na₂SO₄), filtered, and the solvent was removed in vacuo to provide 39 (4.72 g; 96%) as an oil. The crude mixture was used immediately without further purification.

[0136] 3. 5,10,15,20-Tetrakis(n-butoxycarbonyl)porphyrin (40)

[0137] To a foil covered round-bottomed flask equipped with a magnetic stirrer and a N₂inlet was added n-butyl glyoxylate (39, 2.5 g, 19 mmol), CH₂Cl₂(1.9 L), NaCl (0.11 g, 1.9 mmol) and pyrrole (1.33 ml, 19 mmol). The reaction mixture was stirred for 5 min then BF₃.OEt₂(0.71 ml, 5.7 mmol) was added. After a stirring period of 1 h, DDQ (3.27 g, 14.3 mmol) was added and the reaction mixture was stirred overnight. Clarion 550 clay (15 g) was added and the resulting suspension was allowed to stir for 2-3 h, then filtered through a pad of Celite. The solvent was removed in vacuo and the residue was adsorbed onto silica gel (2 g). Purification by column chromatography (gradient elution with 50→100% CH₂Cl₂/hexanes) afforded porphyrin 40 (0.36 g; 11%) as a dark violet solid: ¹H NMR (300 MHz, CDCl₃) δ −3.32 (s, 2H), 1.12 (t, 12H), 1.70 (m, 8H), 2.14 (q, 8H), 5.06 (t, 8H), 9.51(s, 8H).

[0138] 4. [5,10,15,20-Tetrakis(n-butoxycarbonyl)porphyrinato]manganese(III) Chloride (41) and [5-Carboxy-10,15,20-tris(n-butoxycarbony)porphyrinato]manganese(III) Chloride (42)

[0139] A solution of porphyrin 40 (355 mg, 0.50 mmol) and MnCl₂(318 mg, 2.53 mmol) in anhydrous DMF (50 mL) was magnetically stirred and heated to 145° C. for 1 h then exposed to a stream of air for 2 h. The reaction mixture was cooled to room temperature overnight under a stream of air. Evaporation of DMF provided a crude solid mixture which was adsorbed onto silica gel (2 g). Purification by column chromatography (gradient elution with 0-5% MeOH/CH₂Cl₂) provided porphyrins 41 (170 mg) and 42 (10 mg) as solids. For porphyrin 41: mp 200-210° C.; UV-vis λ_max=456.0 nm, ε=1.4×10⁵L/cm-mol; FAB MS m/z=763 [C₄₀H₄₄MnN₄O₈]⁺. For porphyrin 42: mp 200-205° C.; UV-vis λ_max=459.5 nm, ε=7.2×104 L/cm-mol; FAB MS m/z=707, [C₃₆H₃₆MnN₄O₈]⁺.

EXAMPLE 11

XI. [5,15-Bis(n-butoxycarbonyl)porphyrinato]manganese(III) Chloride (45)

[0140]

[0141] 1. 5,15-Bis(n-butoxycarbonyl)porphyrin (44)

[0142] To a foil-covered round-bottom flask equipped with a magnetic stirrer and a N₂inlet was added sequentially n-butyl glyoxylate (39, 1.0 g, 7.7 mmol), CH₂Cl₂(390 mL), NaCl (42 mg, 0.77 mmol) and dipyrromethane (1.12 g, 7.7 mmol). The solution was stirred for 5 min, then BF₃.OEt₂(283 μL, 2.3 mmol) was added and reaction mixture allowed to stir for 30 min. DDQ (1.3 g, 5.8 mmol) was added, and the reaction mixture was stirred for another 30 mm. The solvent was removed in vacuo and the residue was adsorbed onto silica gel (2 g). Purification by column chromatography (gradient elution 50→66% CH₂Cl₂/hexane) provided 44 (137 mg; 7%): ¹H NMR (300 MHz, CDCl₃) δ −3.7 (s, 2H), 1.16 (t, 6H), 1.78 (m, 4H), 2.20 (m, 4H), 5.07 (t, 4H), 9.37 (d, 4H), 9.58 (d, 4H), 10.19 (s, 2H).

[0143] 2. [5,15-Bis(n-butoxycarbonyl)porphyrinato]manganese(III) Chloride (45)

[0144] To a round-bottom flask equipped with a magnetic stirrer was added porphyrin 43 (137 mg, 0.27 mmol), MnCl₂(170 mg, 1.3 mmol) and DMF (110 ml). The reaction mixture was heated to 140° C. After a stirring period of 2 h, the reaction was exposed to a stream of air overnight at 110° C. The solvent was removed in vacuo and the residue was adsorbed onto silica gel. Purification by column chromatography on silica (elution with 5% MeOH/CH₂Cl₂) provided 45 (65 mg; 43%) as a dark solid: mp>300° C.; UV-vis λ_max=563 nm, ε=8.4×10⁴L/cm-mole; FAB MS m/z=563 [C₃₀H₂₈MnN₄O₄]⁺.

EXAMPLE 12

XIII. [5,15-Bis(trifluoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (53) and [5-(trifluoroethoxycarbonyl)porphyrinato]manganese (III) Chloride (54)

[0145]

[0146] 1. 5-Trifluoroethoxycarbonylporphyrin (51) and 5,15-Bis(trifluoroethoxycarbonyl)porphyrin (52)

[0147] To a foil covered round-bottom flask equipped with a magnetic stirrer and a N₂inlet was added consecutively dipyrromethane 17 (Chong, et al, Aust. J. Chem.1969, 22, 229) (1.41 g, 9.6 mmol), CH₂Cl₂(1.15 L), trifluoroethyl glyoxylate (35, 1.6 g, 9.6 mmol) and NaCl (53 mg, 0.96 mmol). The reaction mixture was stirred for 5-10 min, then BF₃.OEt₂(176 μL, 1.43 mmol) was added. After a 30 min stirring period, DDQ (1.63 g, 7.2 mmol) was added and the reaction mixture was stirred overnight. Removal of solvents in vacuo provided a crude product which was adsorbed onto silica gel (2 g). Column chromatographic purification (gradient elution with 50%→80% CH₂Cl₂/hexane) afforded porphyrin 20, porphyrin 51 (38 mg) and porphyrin 52 (54 mg). For porphyrin 51: ¹H NMR (300 MHz, CDCl₃) δ −3.58 (s, 2H), 5.43 (q, 2H), 9.45 (m, 4H), 9.51 (d, 2H), 9.70 (d, 2H), 10.30 (s, 1H), 10.35 (s, 2H). For porphyrin 52: ¹H NMR (300 MHz, CDCl₃) δ −3.11 (s, 2H), 5.44 (q, 4H), 9.50 (d, 4H), 9.70 (d, 4H), 10.42 (s, 2H).

[0148] 2. [5,15-Bis(trifluoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (53)

[0149] To a magnetically stirred solution of porphyrin 31 (54 mg, 0.1 mmol) in anhydrous DMF (60 mL) was added MnCl₂(63 m;, 0.5 mmol). The reaction flask was fitted with a reflux condenser and the solution was heated to 145° C. for 2 h then exposed to a stream of air. Additional MnCl₂(63 mg 0.5 mmol) was added for completion of the reaction. The reaction mixture was heated for an additional 3-4 h then the solution was allowed to cool to room temperature for 48 h under a stream of air. Evaporation of DMF in vacuo provided a crude product that was adsorbed onto silica gel (2 g). Purification by column chromatography (gradient elution with 5→7.5% MeOH/CH₂Cl₂) provided 53 (45 mg; 72%) as a dark solid: mp>300° C.; UV-vis λ_max=451 nm, ε=8×10⁴L/cm-mole; FAB MS m/z=615 [C₂₆H₁₄F₆MnN₄O₄]⁺.

EXAMPLE 13

XV. [5,15-Bis(dimethylamido)-10,20-bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (61)

[0150]

[0151] 1. meso-(N,N-Dimethylamido)dipyrromethane (59)

[0152] In a round-bottom flask equipped with a magnetic stir bar and N₂inlet was placed N,N-dimethyl glyoxamide (56, 2.0 g, 20 mmol), pyrrole (16 mL, 235 mmol) and CH₂Cl₂(40 mL). Trifluoroacetic acid (0.6 mL, 7.8 mmol) was then added. The resulting red-orange solution was stirred overnight at room temperature, transferred into a separatory funnel, diluted with CH₂C₂, then washed with H₂O, saturated aqueous NaHCO₃, H₂O and brine. The organic portion was dried (Na₂SO₄) and filtered. The solvent was removed in vacuo and the residue was adsorbed onto silica gel (5 g). Purification by chromatography (SiO₂, gradient elution with 40% CH₂Cl₂/hexanes→3% CH₃OH/CH₂Cl₂) afforded dipyrromethane 59 as a light brown solid (1.24 g; 31%): ¹H NMR (300 MHz, CDCl₃) δ2.99 (s, 3H), 3.18 (s, 3H), 5.41 (s, 1H), 6.03 (broad s, 2H), 6.07 (m, 2H), 6.62 (broad s, 2H), 9.30 (broad s, 2H).

[0153] 2. 5,15-Bis(dimethylamido)-10,20-bis(ethoxycarbonyl)porphyrin (60)

[0154] To a foil covered round-bottom flask equipped with a magnetic stirrer and a N₂inlet was added consecutively dipyrromethane 59 (500 mg, 2.30 mmol), CH₂Cl₂(230 mL), ethyl glyoxylate (50% in toluene, 470 mg, 2.30 mmol). The reaction mixture was stirred for 5-10 min, then BF₃.OEt₂(57 μL, 0.46 mmol) was added. After a 45 min stirring period, DDQ (392 mg, 1.73 mmol) was added and the reaction mixture was stirred overnight The solvent was removed in vacuo and the residue was adsorbed onto silica gel (4 g). Repeated purification by column chromatography (gradient elution with 0→3% CH₃OH/CH₂Cl₂) afforded porphyrin 60 (7 mg; 1%) as a dark violet solid and as a mixture of atropisomers: ¹H NMR (300 MHz, CDCl₃) δ −3.2 (s, 2H), 1.8 (t, 6H), 2.8 (m, 6H), 3.8 (s, 6H), 5.1 (m, 4H), 9.3 (d, 4H), 9.5 (d, 4H); FAB MS m/z=597 [C₃₂H₃₂N₆O₆+H]⁺.

[0155] 3. [5,15-Bis(dimethylamido)-10,20-bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (61)

[0156] A solution of 60 (7.0 mg, 0.012 mmol) and MnCl₂(15 mg, 0.12 mmol) in DMF (6 mL) was heated at 145° C. for 1 h then exposed to a stream of air. The reaction mixture was heated for an additional 1.5 h then allowed to cool to room temperature overnight and under a stream of air. Additional MnCl₂(15 mg, 0.12 mmol) was added to the reaction mixture and heated at 145° C. for 1.5 h then exposed to a stream of air for 20 min while hot. The reaction mixture was cooled to room temperature. Evaporation of the DMF provided a solid mixture which was adsorbed onto silica gel (1 g). Purification by column chromatography (10% MeOH/CH₂Cl₂) provided porphyrin 61 as a dark red solid: UV-vis λ_max=458.5 nm; FAB MS m/z=649 [C₃₂H₃₀MnN₆O₆]³⁰.

EXAMPLE 14

XVI. [5,15-Bis(dimethylamido)-10,20bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (63)

[0157]

[0158] 1. 5,15-Bis(dimethylamido)-10,20bis(methoxycarbonyl)porphyrin (62)

[0159] To a foil covered round-bottom flask equipped with a magnetic stirrer and a N₂inlet was added consecutively dipyrromethane 59 (915 mg, 4.21 mmol), CH₂Cl₂(400 mL), freshly distilled methyl glyoxylate (370 mg, 4.21 mmol) in CH₂Cl₂(30 mL) and NaCl (25 mg, 0.43 mmol). The reaction mixture was stirred for 5-10 min, then BF₃.OEt₂(160 μL, 1.26 mmol) was added. After a 30 min stirring period, DDQ (1.43 g, 6.32 mmol) was added and the reaction mixture was stirred overnight. The solvent was removed in vacuo and the residue was adsorbed onto silica gel (4 g). Repeated purification by column chromatography (gradient elution with 0→10% CH₃OH/CH₂Cl₂) afforded porphyrin 62 (40 mg; 1.7%) as a dark violet solid mixture of atropisomers: ¹H NMR (300 MHz, CDCl₃) δ −3.1 (s, 2H), 2.71, 2.78 (two singlets, 6H), 3.81 (s, 6H), 4.60 (s, 6H), 9.30 (d, 4H), 9.53 (d, 4H); FAB MS m/z=569 [C₃₀H₂₈N₆O₆+H]⁻.

[0160] 2. [5,15-Bis(dimethylamido)-10,20-bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (63)

[0161] A solution of 62 (41 mg, 0.072 mmol) and MnCl₂(181 mg, 1.44 mmol) in DMF (18 mL) was heated at 145° C. for 1.5 h then exposed to a stream of air. The reaction mixture was heated for an additional 1 h then allowed to cool to room temperature overnight under a stream of air. Evaporation of the DMF provided a solid mixture which was adsorbed onto silica gel (1.5 g). Purification by column chromatography (gradient elution with 5→20% CH₃OH/CH₂Cl₂) provided a dark red solid. The solid was dissolved in CH₂Cl₂(10 mL) and filtered through a fritted funnel. The residual solid was washed with 2% CH₃OH/CH₂Cl₂. The filtrates were combined and the solvent removed in vacuo to afford 63 (10 mg, 21%) as a black solid mixture of atropisomers: mp>300° C.; UV-vis λ_max=458.5 nm, ε=3.33×10⁴L/cm-mol; FAB MS m/z=621 [C₃₀H₂₆MnN₆O₆]⁺.

EXAMPLE 15

XVIII. [5,15-Bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (70) and [5methoxycarbonyl)porphyrinato]manganese(III) Chloride (71)

[0162]

[0163] 1. 5-(Methoxycarbonyl)porphyrin (68) and 5,15bis(methoxycarbonyl)porphyrin (69)

[0164] In a foil covered 3 L round-bottom flask equipped with a magnetic stir bar and a N₂inlet was added consecutively dipyrromethane 17 (2.92 g, 20 mmol), CH₂Cl₂(1900 mL), methyl glyoxylate 7 (1.76 g, 20 mmol) as a solution in CH₂Cl₂(100 mL) and NaCl (118 mg, 2 mmol). The reaction mixture was stirred for 5-10 min, then BF₃.OEt₂(740 μL, 6.0 mmol) was added. After a 30 min stirring period, DDQ (6.81 g, 30 mmol) was added and the solution was stirred for 2 d. The solvent was removed in vacuo producing, a black tar, which was dissolved in CH₂Cl₂/MeOH (99:1) and filtered through a short plug of silica gel. The filtrate was concentrated, then adsorbed onto silica grel (1 g), and purified by column chromatography (gradient elution with 33% hexanes/CH₂Cl₂→100% CH₂Cl₂) to provide porphyins 20, 68 (30 mg, 0.7%), and 69 (61 mg; 1.4%). Porphyrin 68: ¹H NMR (300 MHz, CDCl₃) δ −3.6 (s, 2H), 4.6 (s, 3H), 9.49-9.53 (m, 6H), 9.7 (d, 2H), 10.3-10.5 (m, 3H). Porphyrin 69: ¹H NMR (300 MHz, CDCl₃) δ −3.2 (s, 2H), 4.6 (s, 6H), 9.5 (d, 4H), 9.7 (d, 2H), 10.4 (s, 2H).

[0165] 2. [5,15-Bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (70)

[0166] To a magnetically stirred solution of porphyrin 69 (61 mg, 0.142 mmol) in anhydrous DMF (70 mL) was added MnCl₂(90 mg, 0.71 mmol). The reaction mixture was heated at 150° C. for 2 h then exposed to a stream of air. The reaction solution was heated for an additional 2-3 h, then the solution was allowed to cool to room temperature overnight under a stream of air. Then the reaction mixture was heated again to 150° C. and stirred for another 4 h. Evaporation of DMF in vacuo provided a solid mixture which was adsorbed onto silica gel (1 g). Purification by column chromatography (5% MeOH/CH₂Cl₂) provided compound 70 (25 mg; 34%) as a dark solid: mp>300° C.; UV-vis λ_max=452.0 nm, ε=4.40×10⁴L/cm-mol; FAB MS m/z=479 [C₂₄H₁₆MnN₄O₄]⁺.

EXAMPLE 16

XX. [5,15-Bis(n-butoxycarbonyl)-10,20-bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (79), [10,20-Bis(n-butoxycarbonyl)-5carboxy-15-(methoxycarbonyl)porphyrinato]manganese(III) Chloride (80), [5,15-Bis(n-butoxycarbonyl)-10-(methoxycarbonyl)porphyrinato]manganese(III) Chloride (81) and [5methoxycarbonyl-10,15,20-tri(butoxycarbonyl) porphyrinato]manganese(III) Chloride (82)

[0167]

[0168] 1. (n-Butoxycarbonyl)dipyrromethane (76)

[0169] A solution of n-butyl glyoxylate (39) (3.85 g, 29.6 mmol) in CH₂Cl₂(100 ml) was magnetically stirred under N₂, in a flask covered with foil. Pyrrole (24.6 ml, 355 mmol) was added and the reaction mixture was allowed to stir overnight. A black product mixture was obtained after evaporation of solvents. This material was filtered through a plug of silica using, CH_{hd 2}Cl₂as eluent. Column chromatography of the residue on silica gel (eluent: 1:1 hexane:CH₂Cl₂) provided pure dipyromethane 76 (1.04 g, 14%).

[0170] 2. 5,15-Bis(n-butoxycarbonyl)-10,20-bis(methoxycarbonyl)porphyrin (77) and 5-Methoxycarbonyl-10,15,20-Tris(n-butoxycarbonyl)porphyrin (78)

[0171] In a foil covered, 500 mL three-neck round-bottomed flask equipped with a magnetic stirrer and a N₂inlet was added consecutively methyl glyoxylate (376 mg, 4.27 mmol), dipyrromethane 39 (1.04 g, 4.23 mmol), NaCl (27 mg, 0.46 mmol), and CH₂Cl₂(420 mL). The reaction mixture was stirred for 5-10 min then BF₃.OEt₂(155 μL, 1.26 mmol) was added. After a stirring period of 30 min at room temperature, DDQ (1.43 g, 6.3 mmol) was added. The reaction mixture was stirred for an additional 2 h at room temperature, then the solvent was removed in vacuo. The residue was purified by repeated chromatographic purifications to provide porphyrins 77 (75 ma) and 78 (20 mg). Porphyrin 77: ¹H NMR (300 MHz, CDCl₃) δ −3.41 (s, 2H), 1.11 (t, 6H), 1.69 (m, 4H), 2.12 (m, 4H), 4.59 (s, 6H), 5.05 (t, 4H), 9.49 (s, 8H). Porphyrin 78: ¹H NMR (300 MHz, CDCl₃) δ −3.34 (s, 2H), 1.11 (7,9H), 1.70 (m, 6H), 2.13 (m, 6H), 4.60 (s, 3H), 5.05 (t, 6H), 9.51 (s, 8H).

[0172] 3. [5,15-Bis(n-butoxycarbonyl)-10,20-bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (79), [10,20-Bis(n-butoxycarbonyl)-5-carboxy-15-(methoxycarbonyl)porphyrinato]manganese(III) Chloride (80), [5,15-Bis(n-butoxycarbonyl)-10-(methoxycarbonyl)porphyrinato]manganese(III) Chloride (81)

[0173] A solution of 77 (75 mg, 0.12 mmol) and NInCl₂(163 mg, 1.30 mmol) in DMF (35 mL) was heated at 145° C. for 2 h. The reaction mixture was then exposed to a stream of air as it cooled to room temperature. Evaporation of DMF provided a solid mixture which was adsorbed onto 2 g silica gel. Purification by column chromatography (gradient elution with 0-7.5% MeOH/CH₂C₂) provided porphyrin 79(33 mg). Further purification of the remaining mixed fractions provided porphyrins 80 (10 mg), and 81 (1 mg). Porphyrin 79: mp200-205° C.; UV-vis λ_max=456.0 nm, ε=9.50×10⁴L/cm-mol; FAB MS m/z=679 [C₃₄H₃₂MnN₄O₈]⁺. Porphyrin 80: mp>300° C.; UV-vis λ_max=460.0 nm, ε=8.20×10⁴L/Cm-mol; FAB MS m/z=665 [C₃₃H₃₀MnN₄O₈]⁺. Porphyrin 81: FAB MS m/z =621 [C₃₂H₃₀MnN₄O₆]⁺.

[0174] 4. [5-methoxycarbonyl-10,15,20-tris(n-butoxycarbonyl)porphyriato]manganese(III) Chloride (82)

[0175] A solution of 78 (20 mg, 0.03 mmol) and MnCl₂(28 mg, 0.22 mmol) in DMF (25 mL) was heated at 140° C. for 1.5 h. Additional MnCl₂(26 mg, 0.21 mmol) was added to the reaction mixture. The reaction mixture was exposed to a stream of air and heating was continued for an additional 4 h. The reaction mixture was cooled to room temperature overnight under a stream of air. Evaporation of DMF provided a solid mixture, which was adsorbed onto 2 g silica gel. Purification by column chromatography (gradient elution with 2-7.5% MeOH/CH₂Cl₂) provided porphyrin 82 (6 mg): mp 180-185° C.; UV-vis λ_max=456.0 nm, ε=7.10×10⁴L/cm-mol; FAB MS m/z=721 [C₃₇H₃₈MnN₄O₈]⁻.

EXAMPLE 17

[0176] XII. [5,15-Bis(ethoxycarbonyl)-10,20-bis(ethyl)porphyrinato]manganese(III) Chloride (50)

[0177] 1. meso-(Ethoxycarbonyl)dipyrromethane (47)

[0178] In a round-bottom flask equipped with a magnetic stir bar and N₂inlet was placed ethyl glyoxylate (12.6 g, 0.123 mol), pyrrole (102 mL, 1.48 mol) and CH₂Cl₂(700 mL). Trifluoroacetic acid (3.8 mL, 0.049 mol) was then added. The resulting dark solution was stirred overnight at room temperature, transferred into a separatory funnel, diluted with CH₂Cl₂, then washed with H₂O, saturated aqueous NaHCO₃, H₂O and brine. The organic portion was dried (Na₂SO₄), filtered and the solvent removed in vacuo. The crude product was repeatedly chromatographed on silica gel (elution with 50% CH₂Cl₂/hexanes). Recrystallization from CH₂Cl₂/hexane provided the product 47 as white crystals (9.39 g; 35%): mp70-75° C.; ¹H NMR (300 MHz, CDCl₃) δ1.31 (t, 3H), 4.24 (q, 2H), 5.10 (s, 1H), 6.09 (broad s, 2H), 6.16 (m, 2H), 6.72 (broad s, 2H), 8.45 (broad s, 2H).

[0179] 2. 5,15-Bis(ethoxycarbonyl)-10,20-bis(ethyl)porphyrin (49)

[0180] In a foil-covered flask fitted with an air condensor, dipyrromethane 47 (150 mg, 0.687 mmol) was magnetically stirred in propionic acid (5 mL), H₂O (0.2 mL) and pyridine (17 μL) at 90° C. for 5 min (Neya, S.; Funasaki, N. J Heterocyclic Chem.1997, 34, 689-690). Propionaldehyde (25 μL, 0.34 mmol), was added and the reaction mixture was stirred for 40min. Another portion of propionaldehyde (10 μL, 0.14 mmol) was added to the reaction mixture, stirred for 2 h and diluted with CH₂Cl₂. The organic phase was washed with H₂O, 0.05 N NaOH (2×), and H₂O, dried (Na₂SO₄), filtered and the solvent was removed in vacuo. The residue was dissolved in CH₂Cl₂(250 mL) and DDQ (108 mg, 0.48 mmol) was added. After stirring overnight, the sample was adsorbed onto silica gel (4 g). Purification by column chromatography (gradient elution 50→100% CH₂C₂/hexane) provided porphyrin 46 (12 mg; 10%) as a dark solid: ¹H NMR (300 MHz, CDCl₃) δ1.81 (t, 6H), 2.01 (t, 6H), 5.11-4.99 (m, 8H), 9.44 (d, 4H), 9.54 (d, 4H); FAB MS m/z=511 [C₃₀H₃₀N₄O₄+H]⁺.

[0181] 3. [5,15-Bis(ethoxycarbonyl)-10,20-bis(ethyl)porphyrinato]manganese(III) Chloride (50)

[0182] To a magnetically stirred solution of porphyrin 49 (12 mg, 0.025 mmol) in anhydrous DMF (4 mL) was added MnCl₂(23 mg, 0.19 mmol). The reaction flask was fitted with a reflux condensor and the solution was heated to 125° C.; air was then pumped into the reaction vessel, and the solution was stirred overnight. The flask was allowed to cool to room temperature, then the solvent was removed in vacuo. The crude material was adsorbed onto silica gel (1 g) and chromatography on silica gel (gradient elution 0→6% MeOH/CH₂Cl₂) provided 47 (3.5 mg; 24%) as a dark solid: mp>300° C.; UV-vis λ_max=462.5 nm, ε=3.43×10⁴L/cm-mole; FAB MS m/z=563 [C₃₀H₂₈MnN₄O₄]⁺.

EXAMPLE 18

Attenuation of Hyperoxic Lung Injury by a Novel Catalitic Antioxidant

[0183] Pulmonary toxicity due to hyperoxia is thought to be related to the formation of reactive oxygen species, including superoxide. Increased levels of antioxidant enzymes, such as superoxide dismutases (SOD) and catalase, have been associated with increased survival and adaptation to hyperoxia in rats and mice. The role of acatalytic antioxidant in conferring protection from hyperoxic lung injury to rats was examined. The compound is a manganic porphyrin (AEOL-11201 (see FIG. 1)) with a broad spectrum of antioxidant properties. Male Sprague-Dawley rats were exposed to 100% O₂, 635 mmHG, for 7 days. The animals were injected with the compound at 15 mg/kg, or the vehicle intraperitoneally every 24 hours. Perivascular edema, a marker of hyperoxic lung injury, was evaluated on hematoxylin and eosin stained lung sections. Compared to the air control animals, the oxygen exposed group developed significant perivascular edema. AEOL-11201 significantly reduced the edema of small to medium sized vessels in O₂exposed rats. These results indicate that manganic porphyrins are useful as therapeutic antioxidants in disease states in which reactive oxygen species are involved.

Claims

What is claimed is:

1. A compound of Formula I or Formula II;

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

2. The compound according to claim 1 wherein R₁and R₃are, independently, —CO₂C_1-4alkyl or —CO₂CH₂CX₃, R₂is —H, —CO₂C_1-3alkyl, —CO₂CH₂CX₃, —CON(CH₃)₂or CX₃and R₄is —H, —COOH, —CO₂C_1-3alkyl, —CON(CH₃)₂or —CX₃.

3. The compound according to claim 2 wherein R₁and R₃are, independently, —CO₂C_1-3alkyl, R₂is —CO₂C_1-3alkyl, —CON(CH₃)₂or —CX₃, and R₄is —H, —COOH, —CO₂C_1-3alkyl, —CON(CH₃)₂or —CX₃.

4. The compound according to claim 3 wherein R₁or R₃is —CO₂CH₃, —CO₂CH₂CH₃, or —CON(CH₃)₂, R₂is —CO₂CH₃, —CO₂CH₂CH₃, or CX₃, and R₄is —H, —COOH, —CO₂CH₃, —CO₂CH₂CH₃or CX₃.

5. The compound according to claim 3 wherein R₁, R₂and R₃are, independently, —CO₂CH₃or —CO₂CH₂CH₃, and R₄is —H, —COOH, —CO₂CH₃or —CO₂CH₂CH₃or —CO₂CH₂₂CH₃.

6. The compound according to claim 5 wherein R₁, R₂, R₃and R₄are, independently, —CO₂CH₃or —CO₂CH₂Cl₃.

7. The compound according to claim 1 wherein at least one A is a halogen.

8. The compound according to claim 1 wherein each A is hydrogen.

9. The compound according to claim 1 wherein said compound is of Formula II and M is manganese.

10. The compound according to claim 1 wherein said compound is of Formula II, M is manganese, R₁, R₂, R₃and R₄are, independently, —CO₂CH₃or —CO₂CH₂CH₃, and each A is a hydrogen.

11. A method of protecting a cell from oxidant-induced toxicity comprising contacting said cell with a protective amount of a compound of Formula I or Formula II:

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

12. The method according to claims 11 wherein said compound is of Formula II and M is manganese.

13. The method according to claim 11 wherein said cell is a mammalian cell.

14. A method of treating a patient suffering from a condition that results from or that is exacerbated by oxidant-induced toxicity comprising administering to said patient an effective amount of a compound of Formula I or Formula II:

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

15. The method according to claim 14 wherein said compound is of Formula II and M is manganese.

16. A method of treating a pathological condition of a patient that results from a degradation product of NO, comprising administering to said patient an effective amount of a compound of Formula I or Formula II

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently;

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is;

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃))₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

17. The method according to claim 16 wherein said compound is of Formula II and M is manganese.

18. A method of treating a patient for an inflammatory disease comprising administering to said patient an effective amount of a compound of Formula I or Formula II:

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is,

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

19. The method according to claim 18 wherein said compound is of Formula II and M is manganese.

20. The method according to claim 18 wherein said inflammatory disease is an inflammatory lung disease.

21. The method according to claim 20 wherein said inflammatory lung disease is bronchopulmonary disease.

22. The method according to claim 20 wherein said inflammatory lung disease is asthma.

23. The method according to any one of claims 11, 14, 16 and 18 wherein each A is hydrogen.

Patent Citations (63)

Patent	Date	Inventor	Cited By
US2951799(A)	1960-09-01	Sharp	Applicant
US4614723(A)	1986-09-01	Schmidt	Applicant
US4746735(A)	1988-05-01	Kruper, Jr. et al.	Applicant
US4758422(A)	1988-07-01	Quay	Applicant
US4837221(A)	1989-06-01	Bonnett	Applicant
US4851403(A)	1989-07-01	Picker et al.	Applicant
US4885114(A)	1989-12-01	Gordon et al.	Applicant
US4892941(A)	1990-01-01	Dolphin et al.	Applicant
US4895719(A)	1990-01-01	Radhakrishnam	Applicant
US5171680(A)	1990-08-01	Mullenbach et al.	Applicant
US4963367(A)	1990-10-01	Ecanow	Applicant
US5051337(A)	1991-09-01	Sakoda et al.	Applicant
US5130245(A)	1992-07-01	Marklund et al.	Applicant
US5162519(A)	1992-11-01	Bonnett	Applicant
US5169630(A)	1992-12-01	Okaya et al.	Applicant
US5202317(A)	1993-04-01	Bruice	Applicant
US5217966(A)	1993-06-01	Bruice	Applicant
US5223538(A)	1993-06-01	Fridovich	Applicant
US5227405(A)	1993-07-01	Fridovich	Applicant
US5236914(A)	1993-08-01	Meunier	Applicant
US5236915(A)	1993-08-01	Fiel	Applicant
US5248603(A)	1993-09-01	Marklund et al.	Applicant
US5262532(A)	1993-11-01	Tweedle et al.	Applicant
US5281616(A)	1994-01-01	Dixon et al.	Applicant
US5284647(A)	1994-02-01	Niedballa	Applicant
US5366729(A)	1994-11-01	Marklund et al.	Applicant
US5472691(A)	1995-12-01	Marklund et al.	Applicant
US5493017(A)	1996-02-01	Therien et al.	Applicant
US5599924(A)	1997-02-01	Therien et al.	Applicant
US5674467(A)	1997-10-01	Maier et al.	Applicant
US5747026(A)	1998-05-01	Crapo	Applicant
US5994339(A)	1999-11-01	Crapo et al.	Applicant
US6046188(A)	2000-04-01	Malfroy-Camine et al.	Applicant
US6084093(A)	2000-07-01	Riley et al.	Applicant
US6103714(A)	2000-08-01	Fridovich et al.	Applicant
US6127356(A)	2000-10-01	Crapo et al.	Applicant
EP127797	1984-12-01		Applicant
EP186962	1986-07-01		Applicant
EP282899	1988-09-01		Applicant
EP336879	1989-10-01		Applicant
EP337601	1989-10-01		Applicant
EP345171	1989-12-01		Applicant
EP414915	1991-03-01		Applicant
EP462836	1991-12-01		Applicant
EP524161	1993-01-01		Applicant
EP532327	1993-03-01		Applicant
FR2676738	1992-11-01		Applicant
WO91/04315	1991-04-01		Applicant
WO92/07935	1992-05-01		Applicant
WO92/15099	1992-09-01		Applicant
WO93/02090	1993-02-01		Applicant
WO94/04614	1994-03-01		Applicant
WO95/10185	1995-04-01		Applicant
WO95/31197	1995-11-01		Applicant
WO9609038	1996-03-01		Applicant
WO96/09053	1996-03-01		Applicant
WO96/40223	1996-12-01		Applicant
WO98/33503	1998-06-01		Applicant
WO99/23097	1999-05-01		Applicant
WO99/55388	1999-11-01		Applicant
WO/43395	2000-07-01		Applicant
WO1/26655	2001-04-01		Applicant
WO1/96345	2001-12-01		Applicant

Non-Patent Literature (158)

Collman et al. J. Am. Chem. Soc. 103(3) (1981) 516-533.Applicant
Batinić -Haberle Arch. Biochem. Biophys. 343(2) (1997) 225-233.Applicant
Comhair et al. Lancet 355(9204) (2000) 624 (Medline abstract).Applicant
Rosenfeld et al. Pediatrics 6 (1996) 811-817 (Medline abstract).Applicant
Lee et al. J. Chem. Soc., Perkin Trans. 1 (1997) 1215.Applicant
Freeman and Crapo, “Biology of disease: free radicals and tissue injury”, Lab. Invest. 47(5):412-426 (1982)—Abstract.Applicant
Pietarinen et al, “Catalase and glutathione reductase protection of human alveolar macrophages during oxidant exposure in vitro”, Am. J. Respir. Cell Mol. Biol. 13(4):434-441 (1995)—Abstract.Applicant
Poli, G., “Pathogenesis of liver fibrosis” role of oxidative stress”, Mol. Aspects Med. 21(3):49-98 (2000)—Abstract.Applicant
Delanty and Dichter, “Antioxidant therapy in neurologic disease”, Arch. Neurol. 57(9):1265-1270 (2000)—Abstract.Applicant
Smith et al, “Oxidative stress in Alzheimer's disease”, Biochim. Biophy. Acta 1502(1):139-144 (2000)—Abstract.Applicant
Zalba et al, “Vascular oxidant stress: molecular mechanisms and pathophysiological implications”, J. Physiol. Biochem. 56(1):57-64 (2000)—Abstract.Applicant
Babior, B.M., “Phagocytes and oxidative stress”, Am. J. Med. 109(10:33-44 (2000)—Abstract.Applicant
Dhalla et al, “Status of myocardial antioxidants in ischemia-reperfusion injury”, Cardiovasc. Res. 47(3):446-456 (2000)—Abstract.Applicant
Dhalla et al, “Role of oxidative stress in cardiovascular diseases”, J. Hypertens. 18(6):655-673—Abstract (2000).Applicant
Sohal et al, “Current issues concerning the role of oxidative stress in aging: a perspective”, Results Probl. Cell Differ. 29:45-66 (2000)—Abstract.Applicant
Melov, S., “Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging”, Ann. N.Y. Acad. Sci. 908:219-225 (2000)—Abstract.Applicant
Laight et al, “Antioxidants, diabetes and endothelial dysfunction”, Cardiovasc. Res. 47(3):457-464 (2000)—Abstract.Applicant
Grune et al, “Oxidative stress in anemia”, Clin. Nephrol. 53(1 Suppl):S18-22 (2000)—Abstract.Applicant
Mates and Sanchez-Jimenez, “Role of reactive oxygen species in apoptosis: implications for cancer therapy”, Int. J. Biochem. Cell Biol. 32(2):157-170 (2000)—Abstract.Applicant
Mates et al, “Antioxidant enzymes and human diseases”, Clin. Biochem. 32(8):595-603 (1999)—Abstract.Applicant
Battino et al, “Oxidative injury and inflammatory periodontal diseases: the challenge of anti-oxidants to free radicals and reactive oxygen species”, Crit. Rev. Oral Biol. Med. 10(4):458-476 (1999)—Abstract.Applicant
Simonson et al, “Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I. Physiology and biochemistry”, J. Appl. Physiol. 83(2):550-558 (1997)—Abstract.Applicant
Welty-Wolf et al, “Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates, II. Morphometric analysis”, J. Appl. Physiol 83(2):559-568 (1997)—Abstract.Applicant
Hertz and Cloarec, “Pharmacology of free radicals; recent views on their relation to inflammatory mechanisms”, Life Sci. 34(8):713-720 (1984)—Abstract.Applicant
Esterbauer et al, “The role of lipid peroxidation and antioxidants in oxidative modification of LDL”, Free Radic. Biol. Med. 134(4):341-390 (1992)—Abstract.Applicant
Hall and Braughler, “Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation”, Free Radic. Biol. Med.6(3):303-313 (1989)—Abstract.Applicant
Loeper et al, “Lipid peroxidation and protective enzymes during myocardial infarction”, Clin. Chim. Acta 196(2-3):119-125 (1991)—Abstract.Applicant
Galley et al, “Total antioxidant capacity and lipid peroxidation during liver transplantation”, Clin. Sci. (Lond) 89(3):329-332 (1995)—Abstract/Applicant
Day et al, “Metalloporphyrins are potent inhibitors of lipid peroxidation”, Free Radic. Biol. Med. 26(5-6):730-736 (1999)—Abstract.Applicant
Sheldon, Chapter 1 in Metalloporphyrins in Catalytic Oxidations, Marcel Dekker, Inc. (1994).Applicant
Bors et al, “An expanded function for superoxide dismutase”, Free Radic. Res. Commun. 12-13 Pt. 1:411-417 (1991)—Medline Abstract.Applicant
Crapo and Tierney, “Superoxide dismutase and pulmonary oxygen toxicity”, American Journal of Physiology 226(6):1401-1407 (1974).Applicant
O'hara et al, “Potentiation of radiation-induced cell kill by synthetic metalloporphyrins”, Int. J. Radiat. Oncol. Biol. Phys. 16(4):1049-1052 (1989).Applicant
Lee et al, “Rapid decomposition of peroxynitrite by manganese porphyrin-antioxidant redox couples”, Bioorganic & Medical Chemistry Letters 7(22):2913-2918 (1997).Applicant
Madakyan et al, “New watersoluble metal complexes of meso-tetrakis[3-N-(2′-hydroxy ethyl)pyridyl]porphyrins and their pharmacological activity”, Arm Khim. Zh. 42(11):724-728—Chemical Abstracts 113:653—Abstract No. 114907h (1990).Applicant
Wheelhouse et al, “Cationic Porphyrins as Telomerase Inhibitors; the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA”, J. Am. Chem. Soc. 120(13):3261-3262 (1998).Applicant
Zahedi, “Semiempirical molecular orbital calculations of biliverdin: study of dynamics and energetics of the self-association of a two-electron oxidation product”, Theochem. 531:79-88 (2000).Applicant
Lord, “Redox characteristics of nickel and palladium complexes of the open-chain tetrapyrrole octaethylbilindione: a biliverdin model”, Inorg. Chem. 39(6):1128-1134 (2000).Applicant
Balch, “Isolation and characterization of an iron biliverdin-type complex that is formed along with verdohemochrome during the coupled oxidation of iron (II) octaethylporphyrin”, Am. Chem. Soc. 115(20):9056-9061 (1993).Applicant
Koerner, “Carbon monoxide production during the oxygenation of cobalt complexes of linear etrapyrroles”, Inorg. Chem. 37(5):982-988 (1998).Applicant
Balch, “Solid-state self-association of the two-electron oxidation product of a biliverdin analogue”, J. Chem. Soc. Chem. Commun. 6:643-644 (1995).Applicant
Balch, “Geometric and electronic structure and dioxygen sensitivity of the copper complex of octaethylbilindione, a biliverdin analog”, J. Am. Chem. Soc. 115(25):12206-12207 (1993).Applicant
Falk, “Constributions to the chemistry of pyrrolic pigments”, Tetrahedron 37(4):761-767 (1981).Applicant
Burke, “Photochemical and thermal transformations of phytochrome”, Chem. Physiol. Bile Pigm., Int. Symp., pp. 509-517 (1975).Applicant
Crapo et al, 721195, Document No. 123 :218443 (1995).Applicant
Butje et al, “Electronic Spectra, Resonance Raman Spectra and Solution Properties of Water-soluble (Cu(II), Ni(II) and Co(III) Porphyrins”, Inorg. Chim. Acta 167:97-108 (1990).Applicant
Davila et al, “Sterically-Hindered Zinc Porphyrins for Solar-Energy Conversion”, J. Chem. Soc., Chem. Commun., pp. 525-527 (1987).Applicant
Kaufmann et al, “Separation of the Rotational Isomers of Tetrakis(N-methyl-2-pyridiniumyl)porphyrin and Crystal Sturcture of α, α, α, β-(Tetrakis(N-methyl-2-pyridiniumyl)porphyrin)copper Hexacyanoferrate”, Inorg. Chem. 34:5073-5079 (1995).Applicant
Sari et al, “Interaction of Cationic Porphyrins with DNA: Importance of the Number and Position of the Charges and Minimum Structural Requirements for Intercalation”, Biochemistry 29:4205-4215 (1990).Applicant
Vodzinskii et al, “Porphyrines and Their Derivatives. XX. Synthesis and Properties of 2-Nitro-5,10,15,20-tetraheterylporphyrins”, Russian Journal of Organic Chemistry 34(6):882-885 (1998).Applicant
Hambright et al, “Manganese(III) porphyrin isomers: polarography and stannous ion reduction kinetics”, Porphyrin Chem. Adv., editor: Longo, [Pap. Porphyrin Symp.], pp. 284-292, Meeting Date 1977.Applicant
Tjahjono et al, “Cationic porphyrins bearing diazolium rings: synthesis and their interaction with calf thymus DNA”, Biochemica et Biophisica Acta 1472:333-343 (1999).Applicant
Callot and Schaeffer, “Ring contraction of homoporphyrins to porphyrins, meso-Reactivity of 5,10,15-Triphenylporphin and Porphin”, J. Chem. Research (S):51 (1978).Applicant
Inoue et al, “Expression of a Hybrid Cu/Zn-type Superoxide . . . ,” J. Bio. Chem., vol. 266, No. 25, pp. 16409-16414 (1991).Applicant
Day et al, “Manganic Porphyrins Possess Catalase Activity . . . ,” Arch. Biochem. Biophys., vol. 347, No. 2, pp. 256-262 (1997).Applicant
Tsan, M-F., “Superoxide Dismutase and Pulmonary Oxygen Toxicity,” XP-002074505, pp. 286-290 (1993).Applicant
Foran et al, “Effect of Electrolyte Concentration on Axial Anion Ligation in Manganese(III) Meso-Tetraphenylporphyrin Chlorides”, Inorg. Chem. 31:1463-1470 (1992).Applicant
Milgrom, Facile Aerial Oxidation of a Porphyrin. Part 3. Some Metal Complexes of meso-Tetrakis-(3,5-di-t-butyl-4-hydroxyphenyl)porphyrin, J. Chem. Soc. Perkin Trans. 11:71-79 (1988).Applicant
Bockhorst and Hoehn-Berlage, “An Optimized Synthesis of Manganese meso-Tetra(4-sulfonato-phenyl)porphine: A Tumor-Selective MRI Contrast Agent”, Tetrahedron 50(29):8657-8660 (1994).Applicant
Keinan et al, “Catalytic Antibodies. Circular Dichroism and UV-Vis Studies of Antibody-Metalloporphyrin Interactions”, Inorg. Chem. 31:5433-5438 (1992).Applicant
Marx, “Role of Gene Defect in Heredity ALS Clarified”, Science 261:986 (1993).Applicant
Epp et al, “Superoxide Dismutase Activity of Manganese Chelates”, 76-78 (1986).Applicant
Milgrom et al, “Redox Behaviour of Phenolic Porphyrins in Basic Solutions: A Reappraisal”, Free Rad. Res. 24(1):19-29 (1996).Applicant
Szabo et al, “Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger”, FEBS Letters 381:82-86 (1996).Applicant
Patel et al, “Requirement for Superoxide in Excitotoxic Cell Death”, Neuron 16:345-355 (1996).Applicant
Bamford et al, “The Squalestatins: Synthesis and Biological Activity of Some C3-Modified Analogues; Replacement of a Carboxylic Acid or Methyl Ester with an Isoelectric Heterocyclic Functionality”, J. Med. Chem. 38:3502-3513 (1995).Applicant
Szabo et al, “Peroxynitrite Is Involved in the Pathogenesis of the Vascular Contractile and Energetic Failure in Endotoxic Shock”, Shock Society Meeting (1996).Applicant
Stralin et al, “Effects of Oxidative Stress on Expression of Extracellular Superoxide Dismutase, CuZn-Superoxide Fibroblast”, Biochem. J. 298:347-352 (1994).Applicant
Folz et al, “Extracellular Superoxide Dismutase (SOD3):Tissue-Specific Expression, Genomic Characterization, and Computer-Assisted Sequence Analysis of the Human EC SOD Gene”, Genomics 22:162-171 (1994).Applicant
Clyde et al, “Distribution of Manganese Superoxide Dismutase mRNA in Normal and Hyperoxic Rat Lung”, American Journal of Respiratory Cell and Molecular Biology 8:530-537 (1993).Applicant
Wolberg et al, Electrocical and Electron Paramagnetic Resonance Studies of Metalloporphyrins and Their Electrochemical Oxidation Products:, Journal of the American Chemical Society 92(10):2982-2990 (1970).Applicant
Pasternack et al, “Superoxide Dismutase Activities of an Iron Porphyrin and Other Iron Complexes”, Journal of the American Chemical Society 101(4):1026-1031 (1979).Applicant
Winkelman, James, “The Distribution of Tetraphenylporphinesulfonate in the Tumor-bearing Rat”, Cancer Research 22:589-596 (1962).Applicant
Moisy et al, “Catalytic Oxidation of 2,6-Di-Terbutylphenol by Molecular Oxygen Electroassisted by Poly(Pyrrole-Manganese-Porphyrin)”, New J. Chem. 13:511-514 (1989).Applicant
Malinski et al, “Characterization of Conductive Polymeric Nickel(II) Tetrakis(3-methoxy-4-hydroxy-phenyl)Porphyrin as an Anodic Material for Electrocatalysis”, J. Electrochem. Soc. 138(7):2008-2015 (1991).Applicant
Weinraub et al, “Chemical properties of water-soluble porphyrins. 5. Reactions of some manganese (III) porphyrins with the superoxide and other reducing radicals”, Int. J. Radiat. Biol. 50(4):649-658 (1986) (Abs).Applicant
Fajer et al, “π-Cation Radicals and Dications of Metalloporphyrins”, Journal of the American Chemical Society 92(11):3451-3459 (1970).Applicant
Pasternack et al, “Aggregation of Nickel(II), Coppwer (II), and Zinc(II) Derivatives of Water-Soluble Porphyrins”, Inorganic Chemistry 12(11):2606-2610 (1973).Applicant
Datta-Gupta et al, “Synthetic Porphyrins. I. Synthesis and Spectra of Some para-Substituted meso-Tetraphenylporphines (1)”, J. Heterocycl. Chem. 3:495-502 (1966).Applicant
Harriman et al, “Photochemistry of Manganese Porphyrins Part 2.-Photoreduction”, pp. 1543-1552 (1979).Applicant
Longo et al, “The Synthesis and Som e Physical Properties of ms-Tetra(pentafluorophenyl)-porphin and ms-Tetraphenylporphines (1)”, Notes 6:927-931 (1969).Applicant
Barnitz-McLaughlin et al, “Reactions of FeIII(meso-α,α, α, α-tetrakis[O-[N-methylisonicotinamido)phenyl]porphyrin)5+ and FeIII(meso-tetrakis[N-methylpyridinium-4-yl]porphyrin)5+ with NC-, CO2-”, Inorg. Chem. 32:941-947 (1993).Applicant
Pasternack et al, “On the Aggregation of Meso-Substituted Water-Soluble Porphyrins”, Journal of American Chemical Society 94(13):4511-4517 (1972).Applicant
Datta-Gupta et al, “Synthetic Porphyrins II Preparation and Spectra of Some Metal Chelates of para”, Journal of Substituted-mesa-Tetraphenylporphines, J. of Pharmaceutical Science 57(2):300-304 (1968).Applicant
Boissinot et al, “Rational Design and Expression of a Heparin-Targeted Human Superoxide Dismutase”, Biochemical and Biophysical Research Communication 190(1):250-256 (1993).Applicant
Oury et al, “Cold-induced Brain Edema in Mice”, The Journal of Biological Chemistry 268(21):15394-15398 (1993).Applicant
Oury et al, “Extracellular superoxide dismutase, nitric oxide, and central nervous system O2 toxicity”, Proc. Natl. Acad. Sci. USA 89:9715-9719 (1992).Applicant
Pasternack et al, “Catalyst of the Disproportionation of Superoxide by Metalloporphyrins III”, Journal of Inorganic Biochemistry 15:261-267 (1981).Applicant
Oury et al, “Establishment of Transgenic Mice Expressing Human Extracellular Superoxide Dismutase”, American Review of Respiratory Disease 143(4):A515 (1991), International Conference Supplement Abstracts—No. 236.Applicant
Oury et al, “Transgenic Mice Superexpressing Human Extracellular Superoxide Dismutase Show Increased Resistance to Cold-induced Brain Edema, But are More Susceptible to Hyperbaric Oxygen”, American Review of Respiratory Disease 145(4):A713 (1992), International Conference Supplement Abstracts—No. 211.Applicant
Oury et al, “Immunocytochemical Localization of Extracellular Superoxide Dismutase in Human Lung”, American Review of Respiratory Disease 147(4):A713 (1993), International Conference Supplement Abstracts—No. 246.Applicant
Oury, Tim D., “Extracellular Superoxide Dismutase and Nitric Oxide: Transgenic and Immunocytochemical Studies”, Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pathology in the Graduate School of Duke University (Jun. 17, 1993).Applicant
Gosh, “Substituent Effects on Valence Ionization Potentials of Free Base Porphyrins: Local Density Functional Calculations and Their Relevance of Electrochemical and Photelectron Spectroscopic Studies”, J. Am. Chem. Soc. 117:4691-4699 (1995).Applicant
De Peretti et al, “Imidazol[2,1-b]benzoxazole-3-acetamide derivatives, their preparation, and their therapeutic use”, Chemical Abstracts 121:1016, Abstract No. 121:200896u (1994).Applicant
Oberley et al, “Anticancer activity of metal compounds with superoxide dismutase activity”, Agents and Actions 15(5/6):535-538 (1984).Applicant
Collman et al, “Synthesis of “Face to Face” Porphyrin Dimers Linked by 5,15-Substituents: Potential Binuclear Multielectron Redox Catalysts”, J. Am. Chem. Soc. 103:516-533 (1981).Applicant
Gassman et al, “Electronic Effects of Peripheral Substituents in Porphyrins: X-ray Photoelectron Spectroscopy and ab Initio Self-Consistent Field Calculations”, J. Am. Chem. Soc. 114:9990-10000 (1992).Applicant
Bishop et al, “The Reaction of Thiomides with Phosphorus Ylides”, J. Org. Chem. 56:5079-5091 (1991).Applicant
Picker et al, “Cobalt(III) complexes of water soluble synthetic meso-substituted porphyrins as radiation sensitizers for oxic and hypoxic tumor cells”, 8-Radiation 112:405 (1990) Abstract No. 112:73026d.Applicant
McCord et al, “Superoxide Dismutase-An Enzymic Function for Erythrocuprein”, Biochemisty 492, p. 346 (1968).Applicant
McCord et al, Superoxide Dismutase An Enzymic Function for Erythrocuprein (Hemocuprein), The Journal of Biological Chemistry 244(22):6049-6055 (1969).Applicant
Crapo et al, “Superoxide Dismutase and Oxygen Toxicity”, Clinical Research, p. 222 (1977).Applicant
Crapo et al, “The Failure of Aerosolized Superoxide Dismutase to Modify Pulmonary Oxygen Toxicity”, American Review of Respiratory Disease 115:1027-1033 (1977).Applicant
Joester et al, “Superoxide Dismutase Activity of Cu2+-Amino Acid Chelates”, FEBS Letters 25(1):25-28 (1972).Applicant
Brigelius et al, “Superoxide Dismutase Activity of Low Molecular Weight Cu2+-Chelates Studied by Pulse Radiolysis”, FEBS Letters 47(1):72-75 (1974).Applicant
Sorenson, John R.J., “Copper Chelates as Possible Active Forms of the Antiarthritic Agents”, Journal of Medicinal Chemistry 19(1):135-148 (1976).Applicant
deAlvare et al, “Mechanism of Superoxide Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex”, Biochemical and Biophysical Research Communications 69(3):687-694 (1976).Applicant
Halliwell, Barry, “The Superoxide Dismutase Activity of Iron Complexes”, FEBS Letters 56(1):34-38 (1975).Applicant
McClune et al, “Catalysis of Superoxide Dismutation by Iron-Ethylenediaminetetraacetic Acid Complexes. Mechanism of the Reaction and Evidence for the Direct Formation of an Iron(III)-Ethylenediaminetetraacetic Acid Peroxo Complex from the Reaction of Superoxide with Iron(II)-Ethylenediaminetetraacetic Acid”, Communications to the Editor, pp. 5220-5222 (1977).Applicant
Diguiseppi et al, “Putative Superoxide Dismutase Activity of Iron-EDTA: A Reexamination”, Archives of Biochemistry and Biophysics 203(1):145-150 (1980).Applicant
Robertson, Jr. Et al, “Does Copper-D-Penicillamine Catalyze the Dismutation of O2-?”, Archives of Biochemistry and Biophysics 203(2):830-831 (1980).Applicant
Werringloer et al, “The Integration of Divalent Copper and the Microsomal Electron Transport System”, The Journal of Biological Chemistry, 254(23):11839-11846 (1979).Applicant
Pasternack et al, “Catalyst of the Disproportionation of Superoxide by Metalloporphyrins”, Journal of Inorganic Biochemistry 11:261-267 (1979).Applicant
Archibald et al, Manganese and Defenses against Oxygen Toxicity in Lactobacillus plantarum, Journal of Bacteriology 145(1):442-451 (1981).Applicant
Archibald et al, Manganese, Superoxide Dismutase, Oxygen Tolerance in Some Lactic Acid Bacteria, Journal of Bacteriology 146(3):928-936 (1981).Applicant
Archibald et al, The Scavenging of Superoxide Radical by Manganous Complex: In Vitro, Archives of Biochemistry and Biophysics 214(2):452-463 (1982).Applicant
Archibald et al, Investigations of the State of the Manganese in Lactobacillus plantarum, Archives of Biochemistry and Biophysics 215(2):589-596 (1982).Applicant
Darr et al, “A Mimic of Superoxide Dismutase Activity Based Upon Desferrioxamine B and Manganese(IV)”, Archives of Biochemistry and Biophysics 258(2):351-355 (1987).Applicant
Beyer, Jr., Characterization of a Superoxide Dismutase Mimic Prepared from Desferrioxamine and MnO2, Archives of Biochemistry and Biophysics 271(1):149-156 (1989).Applicant
Faulkner et al, “Characterization of Mn(III) Complexes of Linear and Cyclic Desferrioxamines as Mimics of Superoxide Dismutase Activity”, Archives of Biochemistry and Biophysics 310(2):341-346 (1994).Applicant
Faulkner et al, Stable Mn(III) Porphyrins Mimic Superoxide Dismutase in Vitro and Substitute for It in Vivo, The Journal of Biological Chemistry 269(38):23471-23476 (1994).Applicant
Liochev et al, “A Cationic Manganic Porphyrin Inhibits Uptake of Paraquat by Escherichia coli”, Archives of Biochemistry and Biophysics 321(1):271-275 (1995).Applicant
Peretz et al, “Chemical properties of water-soluble porphyrins 3. The reaction of superoxide radicals with some metalloporphyrins”, Int. J. Radiat. Biol. 42(4):449-456 (1982).Applicant
Baudry et al, “Salen-Manganese Complexes are Superoxide Dismutase-Mimics”, Biochemical and Biophysical Research Communication 192(2):964-968 (1993).Applicant
Gonzalez et al, “EUK-8, a Synthetic Superoxide Dismutase and Catalase Mimetic, Ameliorates Acute Lung Injury in Endotexemic Swine”, The Journal of Pharmacology and Experimental Therapeutics 275(2):798-806 (1995).Applicant
Deune et al, “Prevention of Ischemia-Reperfusion Injury with a Synthetic Metalloprotein Superoxide Dismutase Mimic, SC52608”, Plastic and Reconstructive Surgery 98(4):711-718 (1996).Applicant
Lowe et al, “Comparison of the cardiovascular effects of two novel superoxide dismutase mimetics, SC-55858 and SC-54417, in conscious dogs”, European Journal of Pharmacoloty 304:81-86 (1996).Applicant
Weiss et al, “Manganese-based Superoxide Dismutase Mimetics Inhjibit Neutral Infiltration in Vivo”, The Journal of Biological Chemistry 271(42):26149-26156 (1996).Applicant
Jin et al, “A new route to water soluble porphyrins: phosphonium and ammonium type cationic porphyrins and self-assembly”, Chem. Commun., pp. 1939-1940 (1996).Applicant
Pitié et al, “Oxidation at Carbon-1′ of DNA Deoxyriboses by the Mn-TMPyP/KHSO5 System Results from a Cytochrome P-450-Type Hydroxylation Reaction”, J. Am. Soc. 117:2935-2936 (1995).Applicant
Libby et al, “Cationic Porphyrin Derivatives As Inhibitors of Polyamine Catabolism”, Biochemical Pharmacology 50(9):1527-1530 (1995).Applicant
Ilan et al, “Superoxide Dismuting Activity of an Iron Porphyrin”, Inorg. Nucl. Chem. Letters 17(3/4):93-96 (1981).Applicant
Solomon et al, “Chemical properties of Water-Soluble Porphyrins. 2. The Reaction of Iron(III) Tetrakis(4-N-methylpyridyl)porphyrin with the Superoxide Radical Dioxygen Couple”, J. Phys. Chem. 86:1842-1849 (1982).Applicant
Weinraub et al, “Chemical Properties of Water-Soluble Porphyrins. 1. Equilibria between Some Ligands and Iron(III) Tetrakis (4-N-methylpyridyl)porphyrin”, J. Phys. Chem. 86:1839-1842 (1982).Applicant
Day et al, “A Metalloporphyrin Superoxide Dismutase Mimetic Protects Against Paraquat-Induced Endothelial Cell Injury, in Vitro”, The Journal of Pharmacology and Experimental Therapeutics 275(3):1227-1232 (1995).Applicant
Kariya et al, “Superoxide Dismutase (SOD) Activity with Fe-chlorin e6-Na and Suppressiion of Malignant Tumor Growth in Rats”, Cancer Biotheraphy 10(2):139-145 (1995).Applicant
Liochev et al, A Cationic Manganic Porphyrin Inhibits Uptake of Paraquat by Escherichia Coli, Archives of Biochemistry and Biophysics 321(1):271-275 (1995).Applicant
Ohkawa et al, “Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction”, Analytical Biochemistry 95:351 (1979).Applicant
Yue et al, “Carvedilol, a New Vasodilator and Beta Adrenoceptor Antagonist, is an Antioxidant and Free Radical Scavenger”, The Journal of Pharmacology and Experimental Therapeutics 263:(1992).Applicant
Song et al, “Anti-HIV activities of anionic metalloporphyrins and related compounds”, Antiviral Chemistry and Chemotherapy 8(2):85 (1996).Applicant
Harriman and Porter, “Photochemistry of Manganese Porphyrins”, J. Chem. Soc. 275:1532-1542 (1979).Applicant
Bedioui et al, “Metalloporphyrin-Polypyrrole Film Electrode: Characterization and Catalytic Application”, J. Electroanal. Chem. 207:87-99 (1986).Applicant
Ruoslahti et al, “Arg-Gly-Asp: A Versatile Cell Recognition Signal”, Cell 44:517-518 (1986).Applicant
Kumar et al, “Radioprotection by Antioxidant Enzymes and Enzyme Mimetics”, Pharmac. Ther. 39:301-309 (1988).Applicant
Weiss et al, “Evaluation of Activity of Putative Superoxide Dismutase Mimics”, The Journal of Biological Chemistry 2638(31):23049-23054 (1993).Applicant
Parge et al, “Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase”, Proc. Natl. Acad. Sci. USA 89:6109-6113 (1992).Applicant
Lappin, “Part III Bioinorganic Studies”, Inorganic Reaction Mechanisms 7:334-343 (1981).Applicant
Sharma et al, “Synthesis of amphiphilic 5-(4-N-alkylpyridiniumyl)-10,15,20-triphenylporphyrins and their aggregational properties in different solvent systems”, Chemical Abstracts vol. 123, No. 1 (1995)—Abstract No. 9222q.Applicant
Schneider et al, “Ligand-Porphyrin Complexes: Quantitative Evaluation of Stacking and Ionic Contributions”, J. Org. Chem. 59:7464-7472 (1994).Applicant
Giraudeau et al, “Substituent Effects in the Electroreduction of Porphyrins and Metalloporphyrins”, Journal of the American Chemical Society 101(14):3857-3862 (1979).Applicant
Naruta et al, J. Am. Chem. Soc. 113:3595-3596 (1991).Applicant
Leondiadis et al, J. Org. Chem. 54:6135-6138 (1989).Applicant
Schlözer et al, “Reactivity of Unsubstituted Porphin”, German version: Angew. Chem. 87:388 (1975).Applicant
Elangovan and Krishnan, “Photophysical properties of porphyrin amphiphiles bearing pyridinium alkyl groups”, Chemical Physics Letters 194(1,2):139-146 (1992).Applicant
Madakyan et al, “Some metal complexes of meso-tetrakis(3-N-substituted pyridyl)porphyrins and their bioactivity”, Arm. Khim. Zh. 42(10):642-646 (1989).Applicant
Hambright, Peter, “An acid solvolysis kinetic study of manganese(II)-tetra(2-N-methyipyridyl)porphine”, J. Inorg. Chem. 39:1102-1103 (1977).Applicant
Vergeldt et al, “Intramolecular Interactions in the Ground and Excited State of Tetrakis(N-methylpyridyl)porphyrins”, J. Phys. Chem. 99:4397-4405 (1995).Applicant
Louati et al, “Homophophyrines: Effets D'Une Coupure De Conjugaison Cyclique Sur La Reactivite Redox Des Porphyrines”, Nouv. J. Chim. 2:163-168 (1978).Applicant

Abstract

Description

[0002] The present application claims benefit of U.S. Provisional Application No. 60/082,881, filed Apr. 24, 1998.

TECHNICAL FIELD

BACKGROUND

SUMMARY OF THE INVENTION

[0008] Objects and advantages of the present invention will be clear from the description that follows.

BRIEF DESCRIPTION OF THE DRAWING

[0010] Homogenates

[0012] Oxidation of homogenates

[0014] Lipid peroxidation measurement

[0016] Statistical analyses

DETAILED DESCRIPTION OF THE INVENTION

[0020] The mimetics of the present invention are of the Formula I:

[0021] or pharmaceutically acceptable salt thereof wherein:

[0022] R₁and R₃are, independently:

[0023] —CO₂C_1-4alkyl; or

[0024] —CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

[0025] R₂is:

[0026] —H

[0027] —C_1-4alkyl

[0028] —COOH

[0029] —CO₂C_1-4alkyl,

[0030] —CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

[0031] —CON(CH₃)₂, or

[0032] —CX₃, wherein X is halogen; and

[0033] R₄is:

[0034] —H,

[0035] —C_1-4alkyl

[0036] —COOH,

[0037] —CO₂C_1-4alkyl,

[0038] —CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

[0039] —CON(CH₃)₂, or

[0040] —CX₃, wherein X is halogen.

[0044] Even more preferably, R₁, R₂and R₃are, independently, —CO₂CH₃or —CO₂CH₂CH₃, and R₄is —H, —COOH, —CO₂CH₃or —CO₂CH₂CH₃or —CO₂CH₂CH₃.

[0045] Most preferably, R₁, R₂, R₃and R₄are, independently, —CO₂CH₃or —CO₂CH₂CH₃.

[0046] Specific examples of mimetics of the invention are shown in FIG. 1, together with activity data.

[0048] Where isomers are possible, all such isomers of the herein described mimetics are within the scope of the invention.

[0068] The availability of the mimetics of the invention also makes possible studies of processes mediated by O₂⁻, hydrogen peroxide, nitric oxide and peroxynitrite.

[0071] Certain aspects of the present invention will be described in greater detail in the non-limiting Examples that follow.

EXAMPLE 1

I. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (3), [5-Carboxy-10,15,20-tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (4) and [5,10,15Tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (5)

[0072]

[0073] 1. 5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrin (2)

[0075] 2. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (3)

[0077] 3. [5-Carboxy-10,15,20-tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (4) and [5,10,15-Tris(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (5)

EXAMPLE 2

II. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]zinc(II) (6)

[0079]

[0080] 1. [5,10,15,20-Tetrakis(ethoxycarbonyl)porphyrinato]zinc(II) (6)

EXAMPLE 3

III. [5,10,15,20-Tetrakis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (9) and [5-Carboxy-10,15,20-tris(methoxycarbonyl)porphyrinato]manganese(III) Chloride (10)

[0082]

[0083] 1. 5,10,15,20-Tetrakis(methoxycarbonyl)porphyrin (8)

[0085] 2. [5,10,15,20-Tetrakis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (9)

[0087] 3. [5-Carboxy-10,15,20-tris(methoxycarbonyl)porphyrinato]manganese(III) Chloride (10)

[0088] Porphyrin 10 was also isolated by chromatography from the metalation process above: mp>300° C.; UV-vis λ_max=459.5 nm, ε=8.5×10⁴L/cm-mole; FAB MS m/z=581 [C₂₇H₁₈MnN₄O₈]⁺.

EXAMPLE 4

IV. [5,15-Bis(methoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrinato]manganese(III) Chloride (15) and [5,15-Bis(trifluoromethyl)-10-carboxy-20-(methoxycarbonyl)porphyriato]manganese(III) Chloride (16)

[0089]

[0090] 1. meso-(Trifluoromethyl)dipyrromethane (12) (Nishino, N.; Wagner, R. W.; Lindsey, J. S. J. Org. Chem.1996, 61, 7534-7544.)

[0092] 2. 5,15-Bis(methoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrin (14)

[0094] 3. [5,15-Bis(methoxycarbony)-10,20-bis(trafluoromethyl)porphyrinato]manganese(III) Chloride (15)

EXAMPLE 5

V. [5,15-Bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (21)

[0096]

[0097] 1. 5,15-Bis(ethoxycarbonyl)porphyrin (18)

[0099] 2. 5-(Ethoxycarbonyl)porphyrin (19) and Porphyrin (20)

[0101] 3. [5,15-Bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (21)

EXAMPLE 6

VI. [5,10,15,20-Tetrakis(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (27)

[0103]

[0104] 1. Di-n-propyl d-tartrate (24)

[0106] 2. n-Propyl Glyoxylate (25)

[0108] 3. 5,10,15,20-Tetrakis(n-propoxycarbonyl)porphyrin (26)

[0110] 4. [5,10,15,2-Tetrakis(n-propoxycarbonyl)porphyrnato]manganese(III) Chloride (27)

EXAMPLE 7

VII. [5,15-Bis(n-propoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrinato]manganese(I) Chloride (29)

[0112]

[0113] 1. 5,15-Bis(n-propoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrin (28)

[0115] 2. [5,15-Bis(n-propoxycarbonyl)-10,20-bis(trifluoromethyl)porphyrinato]manganese(III) Chloride (29)

EXAMPLE 8

VIII. [5,15-Bis(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (32) and [5-(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (33)

[0117]

[0118] 1. 5-(n-Propoxycarbonyl)porphyrin (30) and 5,15-Bis(n-propoxycarbonyl)porphyrin (31)

[0120] 2. [5,15-Bis(n-propoxycarbonyl)porphyrinato]manganese(III) Chloride (32)

EXAMPLE 9

IX. [5,10,15,20-Tetrakis(2,2,2-trifluoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (37)

[0122]

[0123] 1. Di-(2,2,2-trifluoroethyl) d-tartrate (34)

[0125] 2. 2,2,2-Trifluoroethyl glyoxylate (35)

[0127] 3. 5,10,15,20-Tetrakis(2,2,2-trifluoroethoxycarbonyl)porphyrin (36)

[0129] 4. [5,10,15,20-Tetrakis(2,2,2-trifuoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (37)

EXAMPLE 10

X. [5,10,15,20-Tetrakis(n-butoxycarbonyl)porphyinato]manganese(III) Chloride (41) and [5Carboxy-10,15,20-tris(n-butoxycarbony)porphyrinato]manganese(III) Chloride (42)

[0131]

[0132] 1. Di-n-butyl d-tartrate (38)

[0134] 2. n-Butyl Glyoxylate (39)

[0136] 3. 5,10,15,20-Tetrakis(n-butoxycarbonyl)porphyrin (40)

[0138] 4. [5,10,15,20-Tetrakis(n-butoxycarbonyl)porphyrinato]manganese(III) Chloride (41) and [5-Carboxy-10,15,20-tris(n-butoxycarbony)porphyrinato]manganese(III) Chloride (42)

EXAMPLE 11

XI. [5,15-Bis(n-butoxycarbonyl)porphyrinato]manganese(III) Chloride (45)

[0140]

[0141] 1. 5,15-Bis(n-butoxycarbonyl)porphyrin (44)

[0143] 2. [5,15-Bis(n-butoxycarbonyl)porphyrinato]manganese(III) Chloride (45)

EXAMPLE 12

XIII. [5,15-Bis(trifluoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (53) and [5-(trifluoroethoxycarbonyl)porphyrinato]manganese (III) Chloride (54)

[0145]

[0146] 1. 5-Trifluoroethoxycarbonylporphyrin (51) and 5,15-Bis(trifluoroethoxycarbonyl)porphyrin (52)

[0148] 2. [5,15-Bis(trifluoroethoxycarbonyl)porphyrinato]manganese(III) Chloride (53)

EXAMPLE 13

XV. [5,15-Bis(dimethylamido)-10,20-bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (61)

[0150]

[0151] 1. meso-(N,N-Dimethylamido)dipyrromethane (59)

[0153] 2. 5,15-Bis(dimethylamido)-10,20-bis(ethoxycarbonyl)porphyrin (60)

[0155] 3. [5,15-Bis(dimethylamido)-10,20-bis(ethoxycarbonyl)porphyrinato]manganese(III) Chloride (61)

EXAMPLE 14

XVI. [5,15-Bis(dimethylamido)-10,20bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (63)

[0157]

[0158] 1. 5,15-Bis(dimethylamido)-10,20bis(methoxycarbonyl)porphyrin (62)

[0160] 2. [5,15-Bis(dimethylamido)-10,20-bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (63)

EXAMPLE 15

XVIII. [5,15-Bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (70) and [5methoxycarbonyl)porphyrinato]manganese(III) Chloride (71)

[0162]

[0163] 1. 5-(Methoxycarbonyl)porphyrin (68) and 5,15bis(methoxycarbonyl)porphyrin (69)

[0165] 2. [5,15-Bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (70)

EXAMPLE 16

XX. [5,15-Bis(n-butoxycarbonyl)-10,20-bis(methoxycarbonyl)porphyrinato]manganese(III) Chloride (79), [10,20-Bis(n-butoxycarbonyl)-5carboxy-15-(methoxycarbonyl)porphyrinato]manganese(III) Chloride (80), [5,15-Bis(n-butoxycarbonyl)-10-(methoxycarbonyl)porphyrinato]manganese(III) Chloride (81) and [5methoxycarbonyl-10,15,20-tri(butoxycarbonyl) porphyrinato]manganese(III) Chloride (82)

[0167]

[0168] 1. (n-Butoxycarbonyl)dipyrromethane (76)

[0170] 2. 5,15-Bis(n-butoxycarbonyl)-10,20-bis(methoxycarbonyl)porphyrin (77) and 5-Methoxycarbonyl-10,15,20-Tris(n-butoxycarbonyl)porphyrin (78)

[0174] 4. [5-methoxycarbonyl-10,15,20-tris(n-butoxycarbonyl)porphyriato]manganese(III) Chloride (82)

EXAMPLE 17

[0176] XII. [5,15-Bis(ethoxycarbonyl)-10,20-bis(ethyl)porphyrinato]manganese(III) Chloride (50)

[0177] 1. meso-(Ethoxycarbonyl)dipyrromethane (47)

[0179] 2. 5,15-Bis(ethoxycarbonyl)-10,20-bis(ethyl)porphyrin (49)

[0181] 3. [5,15-Bis(ethoxycarbonyl)-10,20-bis(ethyl)porphyrinato]manganese(III) Chloride (50)

EXAMPLE 18

Attenuation of Hyperoxic Lung Injury by a Novel Catalitic Antioxidant

Claims

What is claimed is:

1. A compound of Formula I or Formula II;

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

6. The compound according to claim 5 wherein R₁, R₂, R₃and R₄are, independently, —CO₂CH₃or —CO₂CH₂Cl₃.

7. The compound according to claim 1 wherein at least one A is a halogen.

8. The compound according to claim 1 wherein each A is hydrogen.

9. The compound according to claim 1 wherein said compound is of Formula II and M is manganese.

10. The compound according to claim 1 wherein said compound is of Formula II, M is manganese, R₁, R₂, R₃and R₄are, independently, —CO₂CH₃or —CO₂CH₂CH₃, and each A is a hydrogen.

11. A method of protecting a cell from oxidant-induced toxicity comprising contacting said cell with a protective amount of a compound of Formula I or Formula II:

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

12. The method according to claims 11 wherein said compound is of Formula II and M is manganese.

13. The method according to claim 11 wherein said cell is a mammalian cell.

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

15. The method according to claim 14 wherein said compound is of Formula II and M is manganese.

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently;

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is:

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen; and

R₄is;

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃))₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

17. The method according to claim 16 wherein said compound is of Formula II and M is manganese.

18. A method of treating a patient for an inflammatory disease comprising administering to said patient an effective amount of a compound of Formula I or Formula II:

or pharmaceutically acceptable salt thereof, wherein

R₁and R₃are, independently:

—CO₂C_1-4alkyl; or

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3;

R₂is,

—H

—C_1-4alkyl

—COOH

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

R₄is:

—H,

—C_1-4alkyl

—COOH,

—CO₂C_1-4alkyl,

—CO₂(CH₂)_nCX₃, wherein X is halogen and n=1 to 3,

—CON(CH₃)₂, or

—CX₃, wherein X is halogen, and

each A is, independently, hydrogen or halogen,

wherein when said compound is of Formula II, M is a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc and Z⁻ is a counterion.

19. The method according to claim 18 wherein said compound is of Formula II and M is manganese.

20. The method according to claim 18 wherein said inflammatory disease is an inflammatory lung disease.

21. The method according to claim 20 wherein said inflammatory lung disease is bronchopulmonary disease.

22. The method according to claim 20 wherein said inflammatory lung disease is asthma.

23. The method according to any one of claims 11, 14, 16 and 18 wherein each A is hydrogen.

Patent Citations (63)

Patent	Date	Inventor	Cited By
US2951799(A)	1960-09-01	Sharp	Applicant
US4614723(A)	1986-09-01	Schmidt	Applicant
US4746735(A)	1988-05-01	Kruper, Jr. et al.	Applicant
US4758422(A)	1988-07-01	Quay	Applicant
US4837221(A)	1989-06-01	Bonnett	Applicant
US4851403(A)	1989-07-01	Picker et al.	Applicant
US4885114(A)	1989-12-01	Gordon et al.	Applicant
US4892941(A)	1990-01-01	Dolphin et al.	Applicant
US4895719(A)	1990-01-01	Radhakrishnam	Applicant
US5171680(A)	1990-08-01	Mullenbach et al.	Applicant
US4963367(A)	1990-10-01	Ecanow	Applicant
US5051337(A)	1991-09-01	Sakoda et al.	Applicant
US5130245(A)	1992-07-01	Marklund et al.	Applicant
US5162519(A)	1992-11-01	Bonnett	Applicant
US5169630(A)	1992-12-01	Okaya et al.	Applicant
US5202317(A)	1993-04-01	Bruice	Applicant
US5217966(A)	1993-06-01	Bruice	Applicant
US5223538(A)	1993-06-01	Fridovich	Applicant
US5227405(A)	1993-07-01	Fridovich	Applicant
US5236914(A)	1993-08-01	Meunier	Applicant
US5236915(A)	1993-08-01	Fiel	Applicant
US5248603(A)	1993-09-01	Marklund et al.	Applicant
US5262532(A)	1993-11-01	Tweedle et al.	Applicant
US5281616(A)	1994-01-01	Dixon et al.	Applicant
US5284647(A)	1994-02-01	Niedballa	Applicant
US5366729(A)	1994-11-01	Marklund et al.	Applicant
US5472691(A)	1995-12-01	Marklund et al.	Applicant
US5493017(A)	1996-02-01	Therien et al.	Applicant
US5599924(A)	1997-02-01	Therien et al.	Applicant
US5674467(A)	1997-10-01	Maier et al.	Applicant
US5747026(A)	1998-05-01	Crapo	Applicant
US5994339(A)	1999-11-01	Crapo et al.	Applicant
US6046188(A)	2000-04-01	Malfroy-Camine et al.	Applicant
US6084093(A)	2000-07-01	Riley et al.	Applicant
US6103714(A)	2000-08-01	Fridovich et al.	Applicant
US6127356(A)	2000-10-01	Crapo et al.	Applicant
EP127797	1984-12-01		Applicant
EP186962	1986-07-01		Applicant
EP282899	1988-09-01		Applicant
EP336879	1989-10-01		Applicant
EP337601	1989-10-01		Applicant
EP345171	1989-12-01		Applicant
EP414915	1991-03-01		Applicant
EP462836	1991-12-01		Applicant
EP524161	1993-01-01		Applicant
EP532327	1993-03-01		Applicant
FR2676738	1992-11-01		Applicant
WO91/04315	1991-04-01		Applicant
WO92/07935	1992-05-01		Applicant
WO92/15099	1992-09-01		Applicant
WO93/02090	1993-02-01		Applicant
WO94/04614	1994-03-01		Applicant
WO95/10185	1995-04-01		Applicant
WO95/31197	1995-11-01		Applicant
WO9609038	1996-03-01		Applicant
WO96/09053	1996-03-01		Applicant
WO96/40223	1996-12-01		Applicant
WO98/33503	1998-06-01		Applicant
WO99/23097	1999-05-01		Applicant
WO99/55388	1999-11-01		Applicant
WO/43395	2000-07-01		Applicant
WO1/26655	2001-04-01		Applicant
WO1/96345	2001-12-01		Applicant

Non-Patent Literature (158)

Collman et al. J. Am. Chem. Soc. 103(3) (1981) 516-533.Applicant

Batinić -Haberle Arch. Biochem. Biophys. 343(2) (1997) 225-233.Applicant

Comhair et al. Lancet 355(9204) (2000) 624 (Medline abstract).Applicant

Rosenfeld et al. Pediatrics 6 (1996) 811-817 (Medline abstract).Applicant

Lee et al. J. Chem. Soc., Perkin Trans. 1 (1997) 1215.Applicant

Freeman and Crapo, “Biology of disease: free radicals and tissue injury”, Lab. Invest. 47(5):412-426 (1982)—Abstract.Applicant

Pietarinen et al, “Catalase and glutathione reductase protection of human alveolar macrophages during oxidant exposure in vitro”, Am. J. Respir. Cell Mol. Biol. 13(4):434-441 (1995)—Abstract.Applicant

Poli, G., “Pathogenesis of liver fibrosis” role of oxidative stress”, Mol. Aspects Med. 21(3):49-98 (2000)—Abstract.Applicant

Delanty and Dichter, “Antioxidant therapy in neurologic disease”, Arch. Neurol. 57(9):1265-1270 (2000)—Abstract.Applicant

Smith et al, “Oxidative stress in Alzheimer's disease”, Biochim. Biophy. Acta 1502(1):139-144 (2000)—Abstract.Applicant

Zalba et al, “Vascular oxidant stress: molecular mechanisms and pathophysiological implications”, J. Physiol. Biochem. 56(1):57-64 (2000)—Abstract.Applicant

Babior, B.M., “Phagocytes and oxidative stress”, Am. J. Med. 109(10:33-44 (2000)—Abstract.Applicant

Dhalla et al, “Status of myocardial antioxidants in ischemia-reperfusion injury”, Cardiovasc. Res. 47(3):446-456 (2000)—Abstract.Applicant

Dhalla et al, “Role of oxidative stress in cardiovascular diseases”, J. Hypertens. 18(6):655-673—Abstract (2000).Applicant

Sohal et al, “Current issues concerning the role of oxidative stress in aging: a perspective”, Results Probl. Cell Differ. 29:45-66 (2000)—Abstract.Applicant

Melov, S., “Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging”, Ann. N.Y. Acad. Sci. 908:219-225 (2000)—Abstract.Applicant

Laight et al, “Antioxidants, diabetes and endothelial dysfunction”, Cardiovasc. Res. 47(3):457-464 (2000)—Abstract.Applicant

Grune et al, “Oxidative stress in anemia”, Clin. Nephrol. 53(1 Suppl):S18-22 (2000)—Abstract.Applicant

Mates and Sanchez-Jimenez, “Role of reactive oxygen species in apoptosis: implications for cancer therapy”, Int. J. Biochem. Cell Biol. 32(2):157-170 (2000)—Abstract.Applicant

Mates et al, “Antioxidant enzymes and human diseases”, Clin. Biochem. 32(8):595-603 (1999)—Abstract.Applicant

Battino et al, “Oxidative injury and inflammatory periodontal diseases: the challenge of anti-oxidants to free radicals and reactive oxygen species”, Crit. Rev. Oral Biol. Med. 10(4):458-476 (1999)—Abstract.Applicant

Simonson et al, “Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I. Physiology and biochemistry”, J. Appl. Physiol. 83(2):550-558 (1997)—Abstract.Applicant

Welty-Wolf et al, “Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates, II. Morphometric analysis”, J. Appl. Physiol 83(2):559-568 (1997)—Abstract.Applicant

Hertz and Cloarec, “Pharmacology of free radicals; recent views on their relation to inflammatory mechanisms”, Life Sci. 34(8):713-720 (1984)—Abstract.Applicant

Esterbauer et al, “The role of lipid peroxidation and antioxidants in oxidative modification of LDL”, Free Radic. Biol. Med. 134(4):341-390 (1992)—Abstract.Applicant

Hall and Braughler, “Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation”, Free Radic. Biol. Med.6(3):303-313 (1989)—Abstract.Applicant

Loeper et al, “Lipid peroxidation and protective enzymes during myocardial infarction”, Clin. Chim. Acta 196(2-3):119-125 (1991)—Abstract.Applicant

Galley et al, “Total antioxidant capacity and lipid peroxidation during liver transplantation”, Clin. Sci. (Lond) 89(3):329-332 (1995)—Abstract/Applicant

Day et al, “Metalloporphyrins are potent inhibitors of lipid peroxidation”, Free Radic. Biol. Med. 26(5-6):730-736 (1999)—Abstract.Applicant

Sheldon, Chapter 1 in Metalloporphyrins in Catalytic Oxidations, Marcel Dekker, Inc. (1994).Applicant

Bors et al, “An expanded function for superoxide dismutase”, Free Radic. Res. Commun. 12-13 Pt. 1:411-417 (1991)—Medline Abstract.Applicant

Crapo and Tierney, “Superoxide dismutase and pulmonary oxygen toxicity”, American Journal of Physiology 226(6):1401-1407 (1974).Applicant

O'hara et al, “Potentiation of radiation-induced cell kill by synthetic metalloporphyrins”, Int. J. Radiat. Oncol. Biol. Phys. 16(4):1049-1052 (1989).Applicant

Lee et al, “Rapid decomposition of peroxynitrite by manganese porphyrin-antioxidant redox couples”, Bioorganic & Medical Chemistry Letters 7(22):2913-2918 (1997).Applicant

Madakyan et al, “New watersoluble metal complexes of meso-tetrakis[3-N-(2′-hydroxy ethyl)pyridyl]porphyrins and their pharmacological activity”, Arm Khim. Zh. 42(11):724-728—Chemical Abstracts 113:653—Abstract No. 114907h (1990).Applicant

Wheelhouse et al, “Cationic Porphyrins as Telomerase Inhibitors; the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA”, J. Am. Chem. Soc. 120(13):3261-3262 (1998).Applicant

Zahedi, “Semiempirical molecular orbital calculations of biliverdin: study of dynamics and energetics of the self-association of a two-electron oxidation product”, Theochem. 531:79-88 (2000).Applicant

Lord, “Redox characteristics of nickel and palladium complexes of the open-chain tetrapyrrole octaethylbilindione: a biliverdin model”, Inorg. Chem. 39(6):1128-1134 (2000).Applicant

Balch, “Isolation and characterization of an iron biliverdin-type complex that is formed along with verdohemochrome during the coupled oxidation of iron (II) octaethylporphyrin”, Am. Chem. Soc. 115(20):9056-9061 (1993).Applicant

Koerner, “Carbon monoxide production during the oxygenation of cobalt complexes of linear etrapyrroles”, Inorg. Chem. 37(5):982-988 (1998).Applicant

Balch, “Solid-state self-association of the two-electron oxidation product of a biliverdin analogue”, J. Chem. Soc. Chem. Commun. 6:643-644 (1995).Applicant

Balch, “Geometric and electronic structure and dioxygen sensitivity of the copper complex of octaethylbilindione, a biliverdin analog”, J. Am. Chem. Soc. 115(25):12206-12207 (1993).Applicant

Falk, “Constributions to the chemistry of pyrrolic pigments”, Tetrahedron 37(4):761-767 (1981).Applicant

Burke, “Photochemical and thermal transformations of phytochrome”, Chem. Physiol. Bile Pigm., Int. Symp., pp. 509-517 (1975).Applicant

Crapo et al, 721195, Document No. 123 :218443 (1995).Applicant

Butje et al, “Electronic Spectra, Resonance Raman Spectra and Solution Properties of Water-soluble (Cu(II), Ni(II) and Co(III) Porphyrins”, Inorg. Chim. Acta 167:97-108 (1990).Applicant

Davila et al, “Sterically-Hindered Zinc Porphyrins for Solar-Energy Conversion”, J. Chem. Soc., Chem. Commun., pp. 525-527 (1987).Applicant

Kaufmann et al, “Separation of the Rotational Isomers of Tetrakis(N-methyl-2-pyridiniumyl)porphyrin and Crystal Sturcture of α, α, α, β-(Tetrakis(N-methyl-2-pyridiniumyl)porphyrin)copper Hexacyanoferrate”, Inorg. Chem. 34:5073-5079 (1995).Applicant

Sari et al, “Interaction of Cationic Porphyrins with DNA: Importance of the Number and Position of the Charges and Minimum Structural Requirements for Intercalation”, Biochemistry 29:4205-4215 (1990).Applicant

Vodzinskii et al, “Porphyrines and Their Derivatives. XX. Synthesis and Properties of 2-Nitro-5,10,15,20-tetraheterylporphyrins”, Russian Journal of Organic Chemistry 34(6):882-885 (1998).Applicant

Hambright et al, “Manganese(III) porphyrin isomers: polarography and stannous ion reduction kinetics”, Porphyrin Chem. Adv., editor: Longo, [Pap. Porphyrin Symp.], pp. 284-292, Meeting Date 1977.Applicant

Tjahjono et al, “Cationic porphyrins bearing diazolium rings: synthesis and their interaction with calf thymus DNA”, Biochemica et Biophisica Acta 1472:333-343 (1999).Applicant

Callot and Schaeffer, “Ring contraction of homoporphyrins to porphyrins, meso-Reactivity of 5,10,15-Triphenylporphin and Porphin”, J. Chem. Research (S):51 (1978).Applicant

Inoue et al, “Expression of a Hybrid Cu/Zn-type Superoxide . . . ,” J. Bio. Chem., vol. 266, No. 25, pp. 16409-16414 (1991).Applicant

Day et al, “Manganic Porphyrins Possess Catalase Activity . . . ,” Arch. Biochem. Biophys., vol. 347, No. 2, pp. 256-262 (1997).Applicant

Tsan, M-F., “Superoxide Dismutase and Pulmonary Oxygen Toxicity,” XP-002074505, pp. 286-290 (1993).Applicant

Foran et al, “Effect of Electrolyte Concentration on Axial Anion Ligation in Manganese(III) Meso-Tetraphenylporphyrin Chlorides”, Inorg. Chem. 31:1463-1470 (1992).Applicant

Milgrom, Facile Aerial Oxidation of a Porphyrin. Part 3. Some Metal Complexes of meso-Tetrakis-(3,5-di-t-butyl-4-hydroxyphenyl)porphyrin, J. Chem. Soc. Perkin Trans. 11:71-79 (1988).Applicant

Bockhorst and Hoehn-Berlage, “An Optimized Synthesis of Manganese meso-Tetra(4-sulfonato-phenyl)porphine: A Tumor-Selective MRI Contrast Agent”, Tetrahedron 50(29):8657-8660 (1994).Applicant

Keinan et al, “Catalytic Antibodies. Circular Dichroism and UV-Vis Studies of Antibody-Metalloporphyrin Interactions”, Inorg. Chem. 31:5433-5438 (1992).Applicant

Marx, “Role of Gene Defect in Heredity ALS Clarified”, Science 261:986 (1993).Applicant

Epp et al, “Superoxide Dismutase Activity of Manganese Chelates”, 76-78 (1986).Applicant

Milgrom et al, “Redox Behaviour of Phenolic Porphyrins in Basic Solutions: A Reappraisal”, Free Rad. Res. 24(1):19-29 (1996).Applicant

Szabo et al, “Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger”, FEBS Letters 381:82-86 (1996).Applicant

Patel et al, “Requirement for Superoxide in Excitotoxic Cell Death”, Neuron 16:345-355 (1996).Applicant

Bamford et al, “The Squalestatins: Synthesis and Biological Activity of Some C3-Modified Analogues; Replacement of a Carboxylic Acid or Methyl Ester with an Isoelectric Heterocyclic Functionality”, J. Med. Chem. 38:3502-3513 (1995).Applicant

Szabo et al, “Peroxynitrite Is Involved in the Pathogenesis of the Vascular Contractile and Energetic Failure in Endotoxic Shock”, Shock Society Meeting (1996).Applicant

Stralin et al, “Effects of Oxidative Stress on Expression of Extracellular Superoxide Dismutase, CuZn-Superoxide Fibroblast”, Biochem. J. 298:347-352 (1994).Applicant

Folz et al, “Extracellular Superoxide Dismutase (SOD3):Tissue-Specific Expression, Genomic Characterization, and Computer-Assisted Sequence Analysis of the Human EC SOD Gene”, Genomics 22:162-171 (1994).Applicant

Clyde et al, “Distribution of Manganese Superoxide Dismutase mRNA in Normal and Hyperoxic Rat Lung”, American Journal of Respiratory Cell and Molecular Biology 8:530-537 (1993).Applicant

Wolberg et al, Electrocical and Electron Paramagnetic Resonance Studies of Metalloporphyrins and Their Electrochemical Oxidation Products:, Journal of the American Chemical Society 92(10):2982-2990 (1970).Applicant

Pasternack et al, “Superoxide Dismutase Activities of an Iron Porphyrin and Other Iron Complexes”, Journal of the American Chemical Society 101(4):1026-1031 (1979).Applicant

Winkelman, James, “The Distribution of Tetraphenylporphinesulfonate in the Tumor-bearing Rat”, Cancer Research 22:589-596 (1962).Applicant

Moisy et al, “Catalytic Oxidation of 2,6-Di-Terbutylphenol by Molecular Oxygen Electroassisted by Poly(Pyrrole-Manganese-Porphyrin)”, New J. Chem. 13:511-514 (1989).Applicant

Malinski et al, “Characterization of Conductive Polymeric Nickel(II) Tetrakis(3-methoxy-4-hydroxy-phenyl)Porphyrin as an Anodic Material for Electrocatalysis”, J. Electrochem. Soc. 138(7):2008-2015 (1991).Applicant

Weinraub et al, “Chemical properties of water-soluble porphyrins. 5. Reactions of some manganese (III) porphyrins with the superoxide and other reducing radicals”, Int. J. Radiat. Biol. 50(4):649-658 (1986) (Abs).Applicant

Fajer et al, “π-Cation Radicals and Dications of Metalloporphyrins”, Journal of the American Chemical Society 92(11):3451-3459 (1970).Applicant

Pasternack et al, “Aggregation of Nickel(II), Coppwer (II), and Zinc(II) Derivatives of Water-Soluble Porphyrins”, Inorganic Chemistry 12(11):2606-2610 (1973).Applicant

Datta-Gupta et al, “Synthetic Porphyrins. I. Synthesis and Spectra of Some para-Substituted meso-Tetraphenylporphines (1)”, J. Heterocycl. Chem. 3:495-502 (1966).Applicant

Harriman et al, “Photochemistry of Manganese Porphyrins Part 2.-Photoreduction”, pp. 1543-1552 (1979).Applicant

Longo et al, “The Synthesis and Som e Physical Properties of ms-Tetra(pentafluorophenyl)-porphin and ms-Tetraphenylporphines (1)”, Notes 6:927-931 (1969).Applicant

Barnitz-McLaughlin et al, “Reactions of FeIII(meso-α,α, α, α-tetrakis[O-[N-methylisonicotinamido)phenyl]porphyrin)5+ and FeIII(meso-tetrakis[N-methylpyridinium-4-yl]porphyrin)5+ with NC-, CO2-”, Inorg. Chem. 32:941-947 (1993).Applicant

Pasternack et al, “On the Aggregation of Meso-Substituted Water-Soluble Porphyrins”, Journal of American Chemical Society 94(13):4511-4517 (1972).Applicant

Datta-Gupta et al, “Synthetic Porphyrins II Preparation and Spectra of Some Metal Chelates of para”, Journal of Substituted-mesa-Tetraphenylporphines, J. of Pharmaceutical Science 57(2):300-304 (1968).Applicant

Boissinot et al, “Rational Design and Expression of a Heparin-Targeted Human Superoxide Dismutase”, Biochemical and Biophysical Research Communication 190(1):250-256 (1993).Applicant

Oury et al, “Cold-induced Brain Edema in Mice”, The Journal of Biological Chemistry 268(21):15394-15398 (1993).Applicant

Oury et al, “Extracellular superoxide dismutase, nitric oxide, and central nervous system O2 toxicity”, Proc. Natl. Acad. Sci. USA 89:9715-9719 (1992).Applicant

Pasternack et al, “Catalyst of the Disproportionation of Superoxide by Metalloporphyrins III”, Journal of Inorganic Biochemistry 15:261-267 (1981).Applicant

Oury et al, “Establishment of Transgenic Mice Expressing Human Extracellular Superoxide Dismutase”, American Review of Respiratory Disease 143(4):A515 (1991), International Conference Supplement Abstracts—No. 236.Applicant

Oury et al, “Transgenic Mice Superexpressing Human Extracellular Superoxide Dismutase Show Increased Resistance to Cold-induced Brain Edema, But are More Susceptible to Hyperbaric Oxygen”, American Review of Respiratory Disease 145(4):A713 (1992), International Conference Supplement Abstracts—No. 211.Applicant

Oury et al, “Immunocytochemical Localization of Extracellular Superoxide Dismutase in Human Lung”, American Review of Respiratory Disease 147(4):A713 (1993), International Conference Supplement Abstracts—No. 246.Applicant

Oury, Tim D., “Extracellular Superoxide Dismutase and Nitric Oxide: Transgenic and Immunocytochemical Studies”, Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pathology in the Graduate School of Duke University (Jun. 17, 1993).Applicant

Gosh, “Substituent Effects on Valence Ionization Potentials of Free Base Porphyrins: Local Density Functional Calculations and Their Relevance of Electrochemical and Photelectron Spectroscopic Studies”, J. Am. Chem. Soc. 117:4691-4699 (1995).Applicant

De Peretti et al, “Imidazol[2,1-b]benzoxazole-3-acetamide derivatives, their preparation, and their therapeutic use”, Chemical Abstracts 121:1016, Abstract No. 121:200896u (1994).Applicant

Oberley et al, “Anticancer activity of metal compounds with superoxide dismutase activity”, Agents and Actions 15(5/6):535-538 (1984).Applicant

Collman et al, “Synthesis of “Face to Face” Porphyrin Dimers Linked by 5,15-Substituents: Potential Binuclear Multielectron Redox Catalysts”, J. Am. Chem. Soc. 103:516-533 (1981).Applicant

Gassman et al, “Electronic Effects of Peripheral Substituents in Porphyrins: X-ray Photoelectron Spectroscopy and ab Initio Self-Consistent Field Calculations”, J. Am. Chem. Soc. 114:9990-10000 (1992).Applicant

Bishop et al, “The Reaction of Thiomides with Phosphorus Ylides”, J. Org. Chem. 56:5079-5091 (1991).Applicant

Picker et al, “Cobalt(III) complexes of water soluble synthetic meso-substituted porphyrins as radiation sensitizers for oxic and hypoxic tumor cells”, 8-Radiation 112:405 (1990) Abstract No. 112:73026d.Applicant

McCord et al, “Superoxide Dismutase-An Enzymic Function for Erythrocuprein”, Biochemisty 492, p. 346 (1968).Applicant

McCord et al, Superoxide Dismutase An Enzymic Function for Erythrocuprein (Hemocuprein), The Journal of Biological Chemistry 244(22):6049-6055 (1969).Applicant

Crapo et al, “Superoxide Dismutase and Oxygen Toxicity”, Clinical Research, p. 222 (1977).Applicant

Crapo et al, “The Failure of Aerosolized Superoxide Dismutase to Modify Pulmonary Oxygen Toxicity”, American Review of Respiratory Disease 115:1027-1033 (1977).Applicant

Joester et al, “Superoxide Dismutase Activity of Cu2+-Amino Acid Chelates”, FEBS Letters 25(1):25-28 (1972).Applicant

Brigelius et al, “Superoxide Dismutase Activity of Low Molecular Weight Cu2+-Chelates Studied by Pulse Radiolysis”, FEBS Letters 47(1):72-75 (1974).Applicant

Sorenson, John R.J., “Copper Chelates as Possible Active Forms of the Antiarthritic Agents”, Journal of Medicinal Chemistry 19(1):135-148 (1976).Applicant

deAlvare et al, “Mechanism of Superoxide Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex”, Biochemical and Biophysical Research Communications 69(3):687-694 (1976).Applicant

Halliwell, Barry, “The Superoxide Dismutase Activity of Iron Complexes”, FEBS Letters 56(1):34-38 (1975).Applicant

McClune et al, “Catalysis of Superoxide Dismutation by Iron-Ethylenediaminetetraacetic Acid Complexes. Mechanism of the Reaction and Evidence for the Direct Formation of an Iron(III)-Ethylenediaminetetraacetic Acid Peroxo Complex from the Reaction of Superoxide with Iron(II)-Ethylenediaminetetraacetic Acid”, Communications to the Editor, pp. 5220-5222 (1977).Applicant

Diguiseppi et al, “Putative Superoxide Dismutase Activity of Iron-EDTA: A Reexamination”, Archives of Biochemistry and Biophysics 203(1):145-150 (1980).Applicant

Robertson, Jr. Et al, “Does Copper-D-Penicillamine Catalyze the Dismutation of O2-?”, Archives of Biochemistry and Biophysics 203(2):830-831 (1980).Applicant

Werringloer et al, “The Integration of Divalent Copper and the Microsomal Electron Transport System”, The Journal of Biological Chemistry, 254(23):11839-11846 (1979).Applicant

Pasternack et al, “Catalyst of the Disproportionation of Superoxide by Metalloporphyrins”, Journal of Inorganic Biochemistry 11:261-267 (1979).Applicant

Archibald et al, Manganese and Defenses against Oxygen Toxicity in Lactobacillus plantarum, Journal of Bacteriology 145(1):442-451 (1981).Applicant

Archibald et al, Manganese, Superoxide Dismutase, Oxygen Tolerance in Some Lactic Acid Bacteria, Journal of Bacteriology 146(3):928-936 (1981).Applicant

Archibald et al, The Scavenging of Superoxide Radical by Manganous Complex: In Vitro, Archives of Biochemistry and Biophysics 214(2):452-463 (1982).Applicant

Archibald et al, Investigations of the State of the Manganese in Lactobacillus plantarum, Archives of Biochemistry and Biophysics 215(2):589-596 (1982).Applicant

Darr et al, “A Mimic of Superoxide Dismutase Activity Based Upon Desferrioxamine B and Manganese(IV)”, Archives of Biochemistry and Biophysics 258(2):351-355 (1987).Applicant

Beyer, Jr., Characterization of a Superoxide Dismutase Mimic Prepared from Desferrioxamine and MnO2, Archives of Biochemistry and Biophysics 271(1):149-156 (1989).Applicant

Faulkner et al, “Characterization of Mn(III) Complexes of Linear and Cyclic Desferrioxamines as Mimics of Superoxide Dismutase Activity”, Archives of Biochemistry and Biophysics 310(2):341-346 (1994).Applicant

Faulkner et al, Stable Mn(III) Porphyrins Mimic Superoxide Dismutase in Vitro and Substitute for It in Vivo, The Journal of Biological Chemistry 269(38):23471-23476 (1994).Applicant

Liochev et al, “A Cationic Manganic Porphyrin Inhibits Uptake of Paraquat by Escherichia coli”, Archives of Biochemistry and Biophysics 321(1):271-275 (1995).Applicant

Peretz et al, “Chemical properties of water-soluble porphyrins 3. The reaction of superoxide radicals with some metalloporphyrins”, Int. J. Radiat. Biol. 42(4):449-456 (1982).Applicant

Baudry et al, “Salen-Manganese Complexes are Superoxide Dismutase-Mimics”, Biochemical and Biophysical Research Communication 192(2):964-968 (1993).Applicant

Gonzalez et al, “EUK-8, a Synthetic Superoxide Dismutase and Catalase Mimetic, Ameliorates Acute Lung Injury in Endotexemic Swine”, The Journal of Pharmacology and Experimental Therapeutics 275(2):798-806 (1995).Applicant

Deune et al, “Prevention of Ischemia-Reperfusion Injury with a Synthetic Metalloprotein Superoxide Dismutase Mimic, SC52608”, Plastic and Reconstructive Surgery 98(4):711-718 (1996).Applicant

Lowe et al, “Comparison of the cardiovascular effects of two novel superoxide dismutase mimetics, SC-55858 and SC-54417, in conscious dogs”, European Journal of Pharmacoloty 304:81-86 (1996).Applicant

Weiss et al, “Manganese-based Superoxide Dismutase Mimetics Inhjibit Neutral Infiltration in Vivo”, The Journal of Biological Chemistry 271(42):26149-26156 (1996).Applicant

Jin et al, “A new route to water soluble porphyrins: phosphonium and ammonium type cationic porphyrins and self-assembly”, Chem. Commun., pp. 1939-1940 (1996).Applicant

Pitié et al, “Oxidation at Carbon-1′ of DNA Deoxyriboses by the Mn-TMPyP/KHSO5 System Results from a Cytochrome P-450-Type Hydroxylation Reaction”, J. Am. Soc. 117:2935-2936 (1995).Applicant

Libby et al, “Cationic Porphyrin Derivatives As Inhibitors of Polyamine Catabolism”, Biochemical Pharmacology 50(9):1527-1530 (1995).Applicant

Ilan et al, “Superoxide Dismuting Activity of an Iron Porphyrin”, Inorg. Nucl. Chem. Letters 17(3/4):93-96 (1981).Applicant

Solomon et al, “Chemical properties of Water-Soluble Porphyrins. 2. The Reaction of Iron(III) Tetrakis(4-N-methylpyridyl)porphyrin with the Superoxide Radical Dioxygen Couple”, J. Phys. Chem. 86:1842-1849 (1982).Applicant

Weinraub et al, “Chemical Properties of Water-Soluble Porphyrins. 1. Equilibria between Some Ligands and Iron(III) Tetrakis (4-N-methylpyridyl)porphyrin”, J. Phys. Chem. 86:1839-1842 (1982).Applicant

Day et al, “A Metalloporphyrin Superoxide Dismutase Mimetic Protects Against Paraquat-Induced Endothelial Cell Injury, in Vitro”, The Journal of Pharmacology and Experimental Therapeutics 275(3):1227-1232 (1995).Applicant

Kariya et al, “Superoxide Dismutase (SOD) Activity with Fe-chlorin e6-Na and Suppressiion of Malignant Tumor Growth in Rats”, Cancer Biotheraphy 10(2):139-145 (1995).Applicant

Liochev et al, A Cationic Manganic Porphyrin Inhibits Uptake of Paraquat by Escherichia Coli, Archives of Biochemistry and Biophysics 321(1):271-275 (1995).Applicant

Ohkawa et al, “Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction”, Analytical Biochemistry 95:351 (1979).Applicant

Yue et al, “Carvedilol, a New Vasodilator and Beta Adrenoceptor Antagonist, is an Antioxidant and Free Radical Scavenger”, The Journal of Pharmacology and Experimental Therapeutics 263:(1992).Applicant

Song et al, “Anti-HIV activities of anionic metalloporphyrins and related compounds”, Antiviral Chemistry and Chemotherapy 8(2):85 (1996).Applicant

Harriman and Porter, “Photochemistry of Manganese Porphyrins”, J. Chem. Soc. 275:1532-1542 (1979).Applicant

Bedioui et al, “Metalloporphyrin-Polypyrrole Film Electrode: Characterization and Catalytic Application”, J. Electroanal. Chem. 207:87-99 (1986).Applicant

Ruoslahti et al, “Arg-Gly-Asp: A Versatile Cell Recognition Signal”, Cell 44:517-518 (1986).Applicant

Kumar et al, “Radioprotection by Antioxidant Enzymes and Enzyme Mimetics”, Pharmac. Ther. 39:301-309 (1988).Applicant

Weiss et al, “Evaluation of Activity of Putative Superoxide Dismutase Mimics”, The Journal of Biological Chemistry 2638(31):23049-23054 (1993).Applicant

Parge et al, “Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase”, Proc. Natl. Acad. Sci. USA 89:6109-6113 (1992).Applicant

Lappin, “Part III Bioinorganic Studies”, Inorganic Reaction Mechanisms 7:334-343 (1981).Applicant

Sharma et al, “Synthesis of amphiphilic 5-(4-N-alkylpyridiniumyl)-10,15,20-triphenylporphyrins and their aggregational properties in different solvent systems”, Chemical Abstracts vol. 123, No. 1 (1995)—Abstract No. 9222q.Applicant

Schneider et al, “Ligand-Porphyrin Complexes: Quantitative Evaluation of Stacking and Ionic Contributions”, J. Org. Chem. 59:7464-7472 (1994).Applicant

Giraudeau et al, “Substituent Effects in the Electroreduction of Porphyrins and Metalloporphyrins”, Journal of the American Chemical Society 101(14):3857-3862 (1979).Applicant

Naruta et al, J. Am. Chem. Soc. 113:3595-3596 (1991).Applicant

Leondiadis et al, J. Org. Chem. 54:6135-6138 (1989).Applicant

Schlözer et al, “Reactivity of Unsubstituted Porphin”, German version: Angew. Chem. 87:388 (1975).Applicant

Elangovan and Krishnan, “Photophysical properties of porphyrin amphiphiles bearing pyridinium alkyl groups”, Chemical Physics Letters 194(1,2):139-146 (1992).Applicant

Madakyan et al, “Some metal complexes of meso-tetrakis(3-N-substituted pyridyl)porphyrins and their bioactivity”, Arm. Khim. Zh. 42(10):642-646 (1989).Applicant

Hambright, Peter, “An acid solvolysis kinetic study of manganese(II)-tetra(2-N-methyipyridyl)porphine”, J. Inorg. Chem. 39:1102-1103 (1977).Applicant

Vergeldt et al, “Intramolecular Interactions in the Ground and Excited State of Tetrakis(N-methylpyridyl)porphyrins”, J. Phys. Chem. 99:4397-4405 (1995).Applicant

Louati et al, “Homophophyrines: Effets D'Une Coupure De Conjugaison Cyclique Sur La Reactivite Redox Des Porphyrines”, Nouv. J. Chim. 2:163-168 (1978).Applicant